<full-text-retrieval-response xmlns="http://www.elsevier.com/xml/svapi/article/dtd" xmlns:bk="http://www.elsevier.com/xml/bk/dtd" xmlns:cals="http://www.elsevier.com/xml/common/cals/dtd" xmlns:ce="http://www.elsevier.com/xml/common/dtd" xmlns:ja="http://www.elsevier.com/xml/ja/dtd" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:sa="http://www.elsevier.com/xml/common/struct-aff/dtd" xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd" xmlns:tb="http://www.elsevier.com/xml/common/table/dtd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xocs="http://www.elsevier.com/xml/xocs/dtd" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><coredata><prism:url>https://api.elsevier.com/content/article/pii/S0223523420303998</prism:url><dc:identifier>doi:10.1016/j.ejmech.2020.112428</dc:identifier><eid>1-s2.0-S0223523420303998</eid><prism:doi>10.1016/j.ejmech.2020.112428</prism:doi><pii>S0223-5234(20)30399-8</pii><dc:title>Design, synthesis and biological evaluation of novel potent STAT3 inhibitors based on BBI608 for cancer therapy </dc:title><prism:publicationName>European Journal of Medicinal Chemistry</prism:publicationname><prism:aggregationType>Journal</prism:aggregationtype><pubType>fla</pubtype><prism:issn>02235234</prism:issn><prism:volume>201</prism:volume><prism:startingPage>112428</prism:startingpage><prism:pageRange>112428</prism:pagerange><articleNumber>112428</articlenumber><dc:format>text/xml</dc:format><prism:coverDate>2020-09-01</prism:coverdate><prism:coverDisplayDate>1 September 2020</prism:coverdisplaydate><prism:copyright>© 2020 Elsevier Masson SAS. All rights reserved.</prism:copyright><prism:publisher>Elsevier Masson SAS.</prism:publisher><dc:creator>Feng, Kai-Rui</dc:creator><dc:creator>Wang, Feng</dc:creator><dc:creator>Shi, Xin-Wei</dc:creator><dc:creator>Tan, Yun-Xuan</dc:creator><dc:creator>Zhao, Jia-Ying</dc:creator><dc:creator>Zhang, Jian-Wei</dc:creator><dc:creator>Li, Qing-Hua</dc:creator><dc:creator>Lin, Guo-Qiang</dc:creator><dc:creator>Gao, Dingding</dc:creator><dc:creator>Tian, Ping</dc:creator><dc:description>
                  Persistently activated signal transducer and activator of transcription 3 (STAT3) plays an important role in the development of multiple cancers, and therefore is a potential therapeutic target for cancer prevention. Herein, we report the rational design, synthesis, and biological evaluation of novel potent STAT3 inhibitors based on BBI608. Among them, compound A11 exhibited the most potent in vitro tumor cell growth inhibitory activities toward MDA-MB-231, MDA-MB-468 and HepG2 cells with IC50 values as low as 0.67 ± 0.02 μM, 0.77 ± 0.01 μM and 1.24 ± 0.16 μM, respectively. Fluorescence polarization (FP) assay validated the binding of compound A11 in STAT3 SH2 domain with the IC50 value of 5.18 μM. Further mechanistic studies indicated that A11 inhibited the activation of STAT3 (Y705), and thus reduced the expression of STAT3 downstream genes CyclinD1 and C-Myc. Simultaneously, it induced cancer cell S phase arrest and apoptosis in a concentration-dependent manner. An additional in vivo study revealed that A11 suppressed the MDA-MB-231 xenograft tumor growth in mice at the dose of 10 mg/kg (i.p.) without obvious body-weight loss. Finally, molecular docking study further elucidated the binding mode of A11 in STAT3 SH2 domain.
               </dc:description><openaccess>0</openaccess><openaccessArticle>false</openaccessarticle><openaccessType/></openaccesstype><openArchiveArticle>false</openarchivearticle><openaccessSponsorName/></openaccesssponsorname><openaccessSponsorType/></openaccesssponsortype><openaccessUserLicense/></openaccessuserlicense><dcterms:subject>STAT3 inhibitors</dcterms:subject><dcterms:subject>BBI608</dcterms:subject><dcterms:subject>Anti-tumor activity</dcterms:subject><dcterms:subject>Molecular docking</dcterms:subject><link href="https://api.elsevier.com/content/article/pii/S0223523420303998" rel="self"/></link><link href="https://www.sciencedirect.com/science/article/pii/S0223523420303998" rel="scidir"/></link></coredata><objects><object ref="sc1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="556" height="75" size="10913">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303998-sc1.jpg?httpAccept=%2A%2F%2A</object><object ref="gr6" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="538" height="220" size="34206">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303998-gr6.jpg?httpAccept=%2A%2F%2A</object><object ref="fx5" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="35" height="27" size="885">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303998-fx5.jpg?httpAccept=%2A%2F%2A</object><object ref="fx2" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="143" height="83" size="4221">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303998-fx2.jpg?httpAccept=%2A%2F%2A</object><object ref="gr9" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="622" height="340" size="45720">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303998-gr9.jpg?httpAccept=%2A%2F%2A</object><object ref="gr2" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="600" height="181" size="34967">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303998-gr2.jpg?httpAccept=%2A%2F%2A</object><object ref="fx3" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="26" height="20" size="595">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303998-fx3.jpg?httpAccept=%2A%2F%2A</object><object ref="gr1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="711" height="253" size="37869">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303998-gr1.jpg?httpAccept=%2A%2F%2A</object><object ref="fx1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="494" height="200" size="30801">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303998-fx1.jpg?httpAccept=%2A%2F%2A</object><object ref="gr7" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="538" height="328" size="41728">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303998-gr7.jpg?httpAccept=%2A%2F%2A</object><object ref="gr3" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="667" height="583" size="172304">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303998-gr3.jpg?httpAccept=%2A%2F%2A</object><object ref="fx4" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="27" height="26" size="721">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303998-fx4.jpg?httpAccept=%2A%2F%2A</object><object ref="gr12" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="538" height="164" size="45572">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303998-gr12.jpg?httpAccept=%2A%2F%2A</object><object ref="gr4" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="387" height="103" size="9818">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303998-gr4.jpg?httpAccept=%2A%2F%2A</object><object ref="gr10" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="538" height="331" size="39494">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303998-gr10.jpg?httpAccept=%2A%2F%2A</object><object ref="gr8" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="689" height="387" size="57114">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303998-gr8.jpg?httpAccept=%2A%2F%2A</object><object ref="gr11" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="756" height="279" size="56681">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303998-gr11.jpg?httpAccept=%2A%2F%2A</object><object ref="fx6" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="42" height="34" size="1010">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303998-fx6.jpg?httpAccept=%2A%2F%2A</object><object ref="gr5" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="778" height="195" size="27663">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303998-gr5.jpg?httpAccept=%2A%2F%2A</object><object ref="fx7" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="42" height="34" size="1088">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303998-fx7.jpg?httpAccept=%2A%2F%2A</object><object ref="sc1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="30" size="2350">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303998-sc1.sml?httpAccept=%2A%2F%2A</object><object ref="gr6" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="90" size="7919">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303998-gr6.sml?httpAccept=%2A%2F%2A</object><object ref="fx5" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="155" height="120" size="2315">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303998-fx5.sml?httpAccept=%2A%2F%2A</object><object ref="fx2" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="127" size="4054">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303998-fx2.sml?httpAccept=%2A%2F%2A</object><object ref="gr9" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="120" size="7264">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303998-gr9.sml?httpAccept=%2A%2F%2A</object><object ref="gr2" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="66" size="4781">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303998-gr2.sml?httpAccept=%2A%2F%2A</object><object ref="fx3" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="119" height="91" size="1692">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303998-fx3.sml?httpAccept=%2A%2F%2A</object><object ref="gr1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="78" size="4263">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303998-gr1.sml?httpAccept=%2A%2F%2A</object><object ref="fx1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="89" size="6900">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303998-fx1.sml?httpAccept=%2A%2F%2A</object><object ref="gr7" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="134" size="9794">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303998-gr7.sml?httpAccept=%2A%2F%2A</object><object ref="gr3" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="188" height="164" size="31121">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303998-gr3.sml?httpAccept=%2A%2F%2A</object><object ref="fx4" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="122" height="117" size="2142">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303998-fx4.sml?httpAccept=%2A%2F%2A</object><object ref="gr12" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="67" size="12713">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303998-gr12.sml?httpAccept=%2A%2F%2A</object><object ref="gr4" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="59" size="3977">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303998-gr4.sml?httpAccept=%2A%2F%2A</object><object ref="gr10" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="135" size="10389">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303998-gr10.sml?httpAccept=%2A%2F%2A</object><object ref="gr8" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="123" size="7688">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303998-gr8.sml?httpAccept=%2A%2F%2A</object><object ref="gr11" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="81" size="7027">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303998-gr11.sml?httpAccept=%2A%2F%2A</object><object ref="fx6" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="189" height="152" size="2882">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303998-fx6.sml?httpAccept=%2A%2F%2A</object><object ref="gr5" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="55" size="3127">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303998-gr5.sml?httpAccept=%2A%2F%2A</object><object ref="fx7" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="188" height="152" size="2863">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303998-fx7.sml?httpAccept=%2A%2F%2A</object><object ref="sc1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2461" height="334" size="79629">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303998-sc1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr6" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2382" height="976" size="236084">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303998-gr6_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx5" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="155" height="120" size="3970">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303998-fx5_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx2" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="637" height="368" size="27747">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303998-fx2_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr9" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2756" height="1508" size="335286">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303998-gr9_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr2" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2657" height="803" size="250988">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303998-gr2_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx3" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="119" height="91" size="2823">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303998-fx3_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3150" height="1123" size="295934">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303998-gr1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2186" height="886" size="198080">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303998-fx1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr7" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2382" height="1453" size="618472">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303998-gr7_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr3" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2953" height="2579" size="1419232">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303998-gr3_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx4" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="122" height="117" size="3548">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303998-fx4_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr12" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2382" height="724" size="363437">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303998-gr12_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr4" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1714" height="458" size="78597">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303998-gr4_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr10" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2382" height="1466" size="279986">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303998-gr10_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr8" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3051" height="1712" size="433701">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303998-gr8_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr11" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3346" height="1233" size="542235">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303998-gr11_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx6" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="189" height="152" size="4957">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303998-fx6_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr5" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3444" height="864" size="170563">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303998-gr5_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx7" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="188" height="152" size="5087">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303998-fx7_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="mmc1" category="standard" type="APPLICATION" multimediatype="Acrobat PDF file" mimetype="application/pdf" size="2656075">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303998-mmc1.pdf?httpAccept=%2A%2F%2A</object><object ref="am" category="standard" type="AAM-PDF" multimediatype="Acrobat PDF file" mimetype="application/pdf" size="1158033">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303998-am.pdf?httpAccept=%2A%2F%2A</object></objects><scopus-id>85087008504</scopus-id><scopus-eid>2-s2.0-85087008504</scopus-eid><pubmed-id>32603980</pubmed-id><link href="https://api.elsevier.com/content/abstract/scopus_id/85087008504" rel="abstract"/></link><originalText><xocs:doc xsi:schemaLocation="http://www.elsevier.com/xml/xocs/dtd http://null/schema/dtds/document/fulltext/xcr/xocs-article.xsd"><xocs:meta xmlns:xoe="http://www.elsevier.com/xml/xoe/dtd">
      <xocs:content-family>serial</xocs:content-family>
      <xocs:content-type>JL</xocs:content-type>
      <xocs:cid>271932</xocs:cid>
      <xocs:ssids>
         <xocs:ssid type="alllist">291210</xocs:ssid>
         <xocs:ssid type="subj">291732</xocs:ssid>
         <xocs:ssid type="subj">291789</xocs:ssid>
         <xocs:ssid type="subj">291858</xocs:ssid>
         <xocs:ssid type="subj">291928</xocs:ssid>
         <xocs:ssid type="content">31</xocs:ssid>
      </xocs:ssids>
      <xocs:srctitle>European Journal of Medicinal Chemistry</xocs:srctitle>
      <xocs:normalized-srctitle>EUROPEANJOURNALMEDICINALCHEMISTRY</xocs:normalized-srctitle>
      <xocs:orig-load-date yyyymmdd="20200625">2020-06-25</xocs:orig-load-date>
      <xocs:available-online-date yyyymmdd="20200625">2020-06-25</xocs:available-online-date>
      <xocs:vor-load-date yyyymmdd="20200627">2020-06-27</xocs:vor-load-date>
      <xocs:vor-available-online-date yyyymmdd="20200627">2020-06-27</xocs:vor-available-online-date>
      <xocs:ew-transaction-id>2021-02-19T20:43:29</xocs:ew-transaction-id>
      <xocs:eid>1-s2.0-S0223523420303998</xocs:eid>
      <xocs:pii-formatted>S0223-5234(20)30399-8</xocs:pii-formatted>
      <xocs:pii-unformatted>S0223523420303998</xocs:pii-unformatted>
      <xocs:doi>10.1016/j.ejmech.2020.112428</xocs:doi>
      <xocs:item-stage>S300</xocs:item-stage>
      <xocs:item-version-number>S300.3</xocs:item-version-number>
      <xocs:item-weight>FULL-TEXT</xocs:item-weight>
      <xocs:hub-eid>1-s2.0-S0223523420X00146</xocs:hub-eid>
      <xocs:timestamp yyyymmdd="20210219">2021-02-19T22:08:34.091246Z</xocs:timestamp>
      <xocs:dco>0</xocs:dco>
      <xocs:tomb>0</xocs:tomb>
      <xocs:date-search-begin>20200901</xocs:date-search-begin>
      <xocs:year-nav>2020</xocs:year-nav>
      <xocs:indexeddate epoch="1593099486">2020-06-25T15:38:06.038851Z</xocs:indexeddate>
      <xocs:articleinfo>absattachment articleinfo articlenumber articletitlenorm authfirstinitialnorm authfirstsurnamenorm cid cids contenttype copyright crossmark dateloaded dateloadedtxt datesearch datesort dateupdated dco docsubtype doctype doi eid ewtransactionid hubeid indexeddate issn issnnorm itemstage itemtransactionid itemweight openaccess openarchive pg pgfirst pii piinorm pubdatestart pubdatetxt pubyr sectiontitle sortorder srctitle srctitlenorm srctype ssids alllist content subj subheadings suppl tomb volfirst volissue volumelist webpdf webpdfpagecount yearnav figure table e-component body acknowledge affil appendices articletitle auth authfirstini authfull authkeywords authlast footnotes grantnumber grantsponsor grantsponsorid highlightsabst primabst pubtype ref specialabst</xocs:articleinfo>
      <xocs:issns>
         <xocs:issn-primary-formatted>0223-5234</xocs:issn-primary-formatted>
         <xocs:issn-primary-unformatted>02235234</xocs:issn-primary-unformatted>
      </xocs:issns>
      <xocs:crossmark is-crossmark="1">true</xocs:crossmark>
      <xocs:vol-first>201</xocs:vol-first>
      <xocs:volume-list>
         <xocs:volume>201</xocs:volume>
      </xocs:volume-list>
      <xocs:suppl>C</xocs:suppl>
      <xocs:vol-iss-suppl-text>Volume 201</xocs:vol-iss-suppl-text>
      <xocs:sort-order>30</xocs:sort-order>
      <xocs:first-fp>112428</xocs:first-fp>
      <xocs:article-number>112428</xocs:article-number>
      <xocs:pages>
         <xocs:first-page>112428</xocs:first-page>
      </xocs:pages>
      <xocs:cover-date-orig>
         <xocs:start-date>20200901</xocs:start-date>
      </xocs:cover-date-orig>
      <xocs:cover-date-text>1 September 2020</xocs:cover-date-text>
      <xocs:cover-date-start>2020-09-01</xocs:cover-date-start>
      <xocs:cover-date-year>2020</xocs:cover-date-year>
      <xocs:hub-sec>
         <xocs:hub-sec-title>Full papers</xocs:hub-sec-title>
      </xocs:hub-sec>
      <xocs:document-type>article</xocs:document-type>
      <xocs:document-subtype>fla</xocs:document-subtype>
      <xocs:copyright-line>© 2020 Elsevier Masson SAS. All rights reserved.</xocs:copyright-line>
      <xocs:normalized-article-title>DESIGNSYNTHESISBIOLOGICALEVALUATIONNOVELPOTENTSTAT3INHIBITORSBASEDBBI608FORCANCERTHERAPY</xocs:normalized-article-title>
      <xocs:normalized-first-auth-surname>FENG</xocs:normalized-first-auth-surname>
      <xocs:normalized-first-auth-initial>K</xocs:normalized-first-auth-initial>
      <xocs:item-toc>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>1</xocs:item-toc-label>
            <xocs:item-toc-section-title>Introduction</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>2</xocs:item-toc-label>
            <xocs:item-toc-section-title>Results and discussion</xocs:item-toc-section-title>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.1</xocs:item-toc-label>
               <xocs:item-toc-section-title>Chemistry</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.2</xocs:item-toc-label>
               <xocs:item-toc-section-title>Biological assay</xocs:item-toc-section-title>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>2.2.1</xocs:item-toc-label>
                  <xocs:item-toc-section-title>In vitro cell growth inhibitory activity</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>2.2.2</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Fluorescence polarization (FP) assay</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>2.2.3</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Compounds <ce:bold>A11</ce:bold> and <ce:bold>A6</ce:bold> inhibited the phosphorylation of STAT3 and its downstream target proteins</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>2.2.4</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Immunofluorescent assay</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>2.2.5</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Compound <ce:bold>A11</ce:bold> induced apoptosis in cancer cells</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>2.2.6</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Analysis of cell cycle effect</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>2.2.7</xocs:item-toc-label>
                  <xocs:item-toc-section-title>In vivo study of compound <ce:bold>A11</ce:bold>
                  </xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>2.2.8</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Molecular modeling simulations</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
            </xocs:item-toc-entry>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>3</xocs:item-toc-label>
            <xocs:item-toc-section-title>Conclusions</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>4</xocs:item-toc-label>
            <xocs:item-toc-section-title>Experimental section</xocs:item-toc-section-title>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.1</xocs:item-toc-label>
               <xocs:item-toc-section-title>Chemistry</xocs:item-toc-section-title>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.1</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Synthesis of 1-(4,6-dibromo-7-hydroxybenzofuran-2-yl)ethan-1-one (<ce:bold>11</ce:bold>)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.2</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Synthesis of 2-acetyl-6-bromobenzofuran-4,7-dione (<ce:bold>12</ce:bold>)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.3</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Synthesis of compounds <ce:bold>A1</ce:bold>, <ce:bold>A6-A30</ce:bold>
                  </xocs:item-toc-section-title>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.3.1</xocs:item-toc-label>
                     <xocs:item-toc-section-title>2-Acetyl-6-(phenylamino)benzofuran-4,7-dione (<ce:bold>A1</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.3.2</xocs:item-toc-label>
                     <xocs:item-toc-section-title>2-Acetyl-6-(o-tolylamino)benzofuran-4,7-dione (<ce:bold>A6</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.3.3</xocs:item-toc-label>
                     <xocs:item-toc-section-title>2-Acetyl-6-(m-tolylamino)benzofuran-4,7-dione (<ce:bold>A7</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.3.4</xocs:item-toc-label>
                     <xocs:item-toc-section-title>2-Acetyl-6-(p-tolylamino)benzofuran-4,7-dione (<ce:bold>A8</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.3.5</xocs:item-toc-label>
                     <xocs:item-toc-section-title>2-Acetyl-6-((2-methoxyphenyl)amino)benzofuran-4,7-dione (<ce:bold>A9</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.3.6</xocs:item-toc-label>
                     <xocs:item-toc-section-title>2-Acetyl-6-((3-methoxyphenyl)amino)benzofuran-4,7-dione (<ce:bold>A10</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.3.7</xocs:item-toc-label>
                     <xocs:item-toc-section-title>2-Acetyl-6-((4-methoxyphenyl)amino)benzofuran-4,7-dione (<ce:bold>A11</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.3.8</xocs:item-toc-label>
                     <xocs:item-toc-section-title>2-Acetyl-6-((2-fluorophenyl)amino)benzofuran-4,7-dione (<ce:bold>A12</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.3.9</xocs:item-toc-label>
                     <xocs:item-toc-section-title>2-Acetyl-6-((3-fluorophenyl)amino)benzofuran-4,7-dione (<ce:bold>A13</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.3.10</xocs:item-toc-label>
                     <xocs:item-toc-section-title>2-Acetyl-6-((4-fluorophenyl)amino)benzofuran-4,7-dione (<ce:bold>A14</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.3.11</xocs:item-toc-label>
                     <xocs:item-toc-section-title>2-Acetyl-6-((2-(trifluoromethyl)phenyl)amino)benzofuran-4,7-dione (<ce:bold>A15</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.3.12</xocs:item-toc-label>
                     <xocs:item-toc-section-title>2-Acetyl-6-((3-(trifluoromethyl)phenyl)amino)benzofuran-4,7-dione (<ce:bold>A16</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.3.13</xocs:item-toc-label>
                     <xocs:item-toc-section-title>2-Acetyl-6-((4-(trifluoromethyl)phenyl)amino)benzofuran-4,7-dione (<ce:bold>A17</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.3.14</xocs:item-toc-label>
                     <xocs:item-toc-section-title>2-Acetyl-6-((2-ethylphenyl)amino)benzofuran-4,7-dione (<ce:bold>A18</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.3.15</xocs:item-toc-label>
                     <xocs:item-toc-section-title>2-Acetyl-6-((4-(dimethylamino)phenyl)amino)benzofuran-4,7-dione (<ce:bold>A19</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.3.16</xocs:item-toc-label>
                     <xocs:item-toc-section-title>2-Acetyl-6-((4-isopropoxyphenyl)amino)benzofuran-4,7-dione (<ce:bold>A20</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.3.17</xocs:item-toc-label>
                     <xocs:item-toc-section-title>2-Acetyl-6-((4-methoxy-2-methylphenyl)amino)benzofuran-4,7-dione (<ce:bold>A21</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.3.18</xocs:item-toc-label>
                     <xocs:item-toc-section-title>2-Acetyl-6-((2,6-dimethylphenyl)amino)benzofuran-4,7-dione (<ce:bold>A22</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.3.19</xocs:item-toc-label>
                     <xocs:item-toc-section-title>2-Acetyl-6-((4-methoxy-2,6-dimethylphenyl)amino)benzofuran-4,7-dione (<ce:bold>A23</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.3.20</xocs:item-toc-label>
                     <xocs:item-toc-section-title>2-acetyl-6-((3,4-dimethylphenyl)amino)benzofuran-4,7-dione (<ce:bold>A24</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.3.21</xocs:item-toc-label>
                     <xocs:item-toc-section-title>2-Acetyl-6-((3-fluoro-5-methylphenyl)amino)benzofuran-4,7-dione (<ce:bold>A25</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.3.22</xocs:item-toc-label>
                     <xocs:item-toc-section-title>2-Acetyl-6-(cyclopropylamino)benzofuran-4,7-dione (<ce:bold>A26</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.3.23</xocs:item-toc-label>
                     <xocs:item-toc-section-title>2-Acetyl-6-(cyclobutylamino)benzofuran-4,7-dione (<ce:bold>A27</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.3.24</xocs:item-toc-label>
                     <xocs:item-toc-section-title>2-Acetyl-6-(cyclopentylamino)benzofuran-4,7-dione (<ce:bold>A28</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.3.25</xocs:item-toc-label>
                     <xocs:item-toc-section-title>2-Acetyl-6-(cyclohexylamino)benzofuran-4,7-dione (<ce:bold>A29</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.3.26</xocs:item-toc-label>
                     <xocs:item-toc-section-title>2-Acetyl-6-((tetrahydro-2H-pyran-4-yl)amino)benzofuran-4,7-dione (<ce:bold>A30</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
               </xocs:item-toc-entry>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.2</xocs:item-toc-label>
               <xocs:item-toc-section-title>Biological evaluation</xocs:item-toc-section-title>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.2.1</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Cell lines culture</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.2.2</xocs:item-toc-label>
                  <xocs:item-toc-section-title>In vitro cell growth inhibitory activity assays</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.2.3</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Fluorescence polarization assay</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.2.4</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Western blot analysis</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.2.5</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Cell immunofluorescent assay</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.2.6</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Flow cytometry analysis of apoptotic cells</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.2.7</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Cell cycle effect</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.2.8</xocs:item-toc-label>
                  <xocs:item-toc-section-title>In vivo studies</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.2.9</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Tissue immunofluorescent assay</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.3</xocs:item-toc-label>
               <xocs:item-toc-section-title>Molecular docking</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.4</xocs:item-toc-label>
               <xocs:item-toc-section-title>X-ray crystal structure determination of compound <ce:bold>A24</ce:bold>
               </xocs:item-toc-section-title>
            </xocs:item-toc-entry>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:acknowledgment">
            <xocs:item-toc-section-title>Acknowledgement</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:appendices">
            <xocs:item-toc-label>Appendix A</xocs:item-toc-label>
            <xocs:item-toc-section-title>Supplementary data</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:bibliography">
            <xocs:item-toc-section-title>References</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
      </xocs:item-toc>
      <xocs:references>
         <xocs:ref-info refid="sref1">
            <xocs:ref-normalized-surname>DARNELL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2002</xocs:ref-pub-year>
            <xocs:ref-first-fp>740</xocs:ref-first-fp>
            <xocs:ref-last-lp>749</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref2">
            <xocs:ref-normalized-surname>MIKLOSSY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>611</xocs:ref-first-fp>
            <xocs:ref-last-lp>629</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>G</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref3">
            <xocs:ref-normalized-surname>FLETCHER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>825</xocs:ref-first-fp>
            <xocs:ref-last-lp>833</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref4">
            <xocs:ref-normalized-surname>BARTON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2004</xocs:ref-pub-year>
            <xocs:ref-first-fp>11</xocs:ref-first-fp>
            <xocs:ref-last-lp>20</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>B</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref5">
            <xocs:ref-normalized-surname>YU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2004</xocs:ref-pub-year>
            <xocs:ref-first-fp>97</xocs:ref-first-fp>
            <xocs:ref-last-lp>105</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref6">
            <xocs:ref-normalized-surname>YU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>737</xocs:ref-first-fp>
            <xocs:ref-last-lp>746</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref7">
            <xocs:ref-normalized-surname>TURKSON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2001</xocs:ref-pub-year>
            <xocs:ref-first-fp>45443</xocs:ref-first-fp>
            <xocs:ref-last-lp>45455</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref8">
            <xocs:ref-normalized-surname>MCDANIEL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>8226</xocs:ref-first-fp>
            <xocs:ref-last-lp>8238</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref9">
            <xocs:ref-normalized-surname>KOSKELA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>1905</xocs:ref-first-fp>
            <xocs:ref-last-lp>1913</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref10">
            <xocs:ref-normalized-surname>YU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-first-fp>41</xocs:ref-first-fp>
            <xocs:ref-last-lp>51</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref11">
            <xocs:ref-normalized-surname>VILLARINO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>21</xocs:ref-first-fp>
            <xocs:ref-last-lp>27</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref12">
            <xocs:ref-normalized-surname>JOHNSON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>234</xocs:ref-first-fp>
            <xocs:ref-last-lp>248</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref13">
            <xocs:ref-normalized-surname>DARNELL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2002</xocs:ref-pub-year>
            <xocs:ref-first-fp>740</xocs:ref-first-fp>
            <xocs:ref-last-lp>749</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref14">
            <xocs:ref-normalized-surname>HUANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2020</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>Q</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref15">
            <xocs:ref-normalized-surname>SONG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2005</xocs:ref-pub-year>
            <xocs:ref-first-fp>4700</xocs:ref-first-fp>
            <xocs:ref-last-lp>4705</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref16">
            <xocs:ref-normalized-surname>LIN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>39</xocs:ref-first-fp>
            <xocs:ref-last-lp>50</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref17">
            <xocs:ref-normalized-surname>YU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>4402</xocs:ref-first-fp>
            <xocs:ref-last-lp>4412</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>W</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref18">
            <xocs:ref-normalized-surname>SCHUST</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-first-fp>1235</xocs:ref-first-fp>
            <xocs:ref-last-lp>1242</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref19">
            <xocs:ref-normalized-surname>REN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>454</xocs:ref-first-fp>
            <xocs:ref-last-lp>459</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>X</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref20">
            <xocs:ref-normalized-surname>SIDDIQUEE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-first-fp>7391</xocs:ref-first-fp>
            <xocs:ref-last-lp>7396</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref21">
            <xocs:ref-normalized-surname>ZHANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>1398</xocs:ref-first-fp>
            <xocs:ref-last-lp>1409</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>X</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref22">
            <xocs:ref-normalized-surname>YU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>2718</xocs:ref-first-fp>
            <xocs:ref-last-lp>2731</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>W</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref23">
            <xocs:ref-normalized-surname>LI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>1839</xocs:ref-first-fp>
            <xocs:ref-last-lp>1844</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref24">
            <xocs:ref-normalized-surname>GUO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>752</xocs:ref-first-fp>
            <xocs:ref-last-lp>764</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref25">
            <xocs:ref-normalized-surname>ZHANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>538</xocs:ref-first-fp>
            <xocs:ref-last-lp>550</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>W</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref26">
            <xocs:ref-normalized-surname>CAI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>236</xocs:ref-first-fp>
            <xocs:ref-last-lp>251</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>G</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref27">
            <xocs:ref-normalized-surname>ZHANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>1098</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>W</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref28">
            <xocs:ref-normalized-surname>ZHANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>301</xocs:ref-first-fp>
            <xocs:ref-last-lp>310</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref29">
            <xocs:ref-normalized-surname>GAO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>2549</xocs:ref-first-fp>
            <xocs:ref-last-lp>2558</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref30">
            <xocs:ref-normalized-surname>LAI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>6549</xocs:ref-first-fp>
            <xocs:ref-last-lp>6558</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref31">
            <xocs:ref-normalized-surname>WANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>218</xocs:ref-first-fp>
            <xocs:ref-last-lp>232</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>X</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref32">
            <xocs:ref-normalized-surname>BAI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>498</xocs:ref-first-fp>
            <xocs:ref-last-lp>511</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref33">
            <xocs:ref-normalized-surname>ZHOU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>11280</xocs:ref-first-fp>
            <xocs:ref-last-lp>11300</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref34">
            <xocs:ref-normalized-surname>BEEBE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>74</xocs:ref-first-fp>
            <xocs:ref-last-lp>91</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref35">
            <xocs:ref-normalized-surname>FURTEK</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>308</xocs:ref-first-fp>
            <xocs:ref-last-lp>318</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref36">
            <xocs:ref-normalized-surname>DEBNATH</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>6645</xocs:ref-first-fp>
            <xocs:ref-last-lp>6668</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>B</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref37"/></xocs:ref-info>
         <xocs:ref-info refid="sref38">
            <xocs:ref-normalized-surname>LI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>543</xocs:ref-first-fp>
            <xocs:ref-last-lp>554</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref39">
            <xocs:ref-normalized-surname>ZHOU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>39</xocs:ref-first-fp>
            <xocs:ref-last-lp>50</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Q</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref40">
            <xocs:ref-normalized-surname>REICHSTEIN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>7273</xocs:ref-first-fp>
            <xocs:ref-last-lp>7284</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref41">
            <xocs:ref-normalized-surname>BANNWITZ</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>6226</xocs:ref-first-fp>
            <xocs:ref-last-lp>6239</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref42">
            <xocs:ref-normalized-surname>SONE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
            <xocs:ref-normalized-srctitle>3SUBSTITUTEDCARBONYLNAPHTHO23BFURANEDERIVATIVEPHARMACEUTICALLYACCEPTABLESALT</xocs:ref-normalized-srctitle>
         </xocs:ref-info>
         <xocs:ref-info refid="sref43">
            <xocs:ref-normalized-surname>CAI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>X</xocs:ref-normalized-initial>
            <xocs:ref-normalized-srctitle>CN107501279A20171222LANGUAGECHINESEDATABASECAPLUS</xocs:ref-normalized-srctitle>
            <xocs:ref-normalized-article-title>PROCESSFORPREPARATIONFURO23GQUINOLINE49DIONECOMPOUNDMEDICALAPPLICATIONFAMINGZHUANLISHENQING</xocs:ref-normalized-article-title>
         </xocs:ref-info>
         <xocs:ref-info refid="sref44">
            <xocs:ref-normalized-surname>BOLIBRUKH</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>2765</xocs:ref-first-fp>
            <xocs:ref-last-lp>2768</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref45">
            <xocs:ref-normalized-surname>BORAH</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>8309</xocs:ref-first-fp>
            <xocs:ref-last-lp>8316</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref46">
            <xocs:ref-normalized-surname>CCDCACONTAINSTHESUPPLEMENTARYCRYSTALLOGRAPHICDATAFORTHISPAPER</xocs:ref-normalized-surname>
         </xocs:ref-info>
         <xocs:ref-info refid="sref47">
            <xocs:ref-normalized-surname>SCHUST</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2004</xocs:ref-pub-year>
            <xocs:ref-first-fp>114</xocs:ref-first-fp>
            <xocs:ref-last-lp>118</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
      </xocs:references>
      <xocs:refkeys>
         <xocs:refkey3>FENGX2020X112428</xocs:refkey3>
         <xocs:refkey4ai>FENGX2020X112428XK</xocs:refkey4ai>
      </xocs:refkeys>
      <xocs:open-access>
         <xocs:oa-article-status is-open-access="0" is-open-archive="0"/></xocs:oa-article-status>
      </xocs:open-access>
      <xocs:open-research>
         <xocs:or-embargo-opening-date>2022-06-27T00:00:00.000Z</xocs:or-embargo-opening-date>
      </xocs:open-research>
      <xocs:self-archiving>
         <xocs:sa-start-date>2022-06-27T00:00:00.000Z</xocs:sa-start-date>
         <xocs:sa-user-license>http://creativecommons.org/licenses/by-nc-nd/4.0/</xocs:sa-user-license>
      </xocs:self-archiving>
      <xocs:copyright-info>
         <xocs:cp-notices>
            <xocs:cp-notice lang="en">© 2020 Elsevier Masson SAS. All rights reserved.</xocs:cp-notice>
         </xocs:cp-notices>
      </xocs:copyright-info>
      <xocs:funding-list has-funding-info="1">
         <xocs:funding-addon-generated-timestamp>2020-06-22T00:22:47.971Z</xocs:funding-addon-generated-timestamp>
         <xocs:funding-addon-type>http://vtw.elsevier.com/data/voc/AddOnTypes/50.7/eoas</xocs:funding-addon-type>
         <xocs:funding>
            <xocs:funding-agency-acronym>STCSM</xocs:funding-agency-acronym>
            <xocs:funding-agency>Science and Technology Commission of Shanghai Municipality</xocs:funding-agency>
            <xocs:funding-agency-id>http://data.elsevier.com/vocabulary/SciValFunders/501100003399</xocs:funding-agency-id>
            <xocs:funding-agency-country>http://sws.geonames.org/1814991</xocs:funding-agency-country>
         </xocs:funding>
         <xocs:funding>
            <xocs:funding-agency>China Postdoctoral Science Foundation</xocs:funding-agency>
            <xocs:funding-agency-id>http://data.elsevier.com/vocabulary/SciValFunders/501100002858</xocs:funding-agency-id>
            <xocs:funding-agency-country>http://sws.geonames.org/1814991</xocs:funding-agency-country>
         </xocs:funding>
         <xocs:funding>
            <xocs:funding-agency-acronym>NSFC</xocs:funding-agency-acronym>
            <xocs:funding-agency>National Natural Science Foundation of China</xocs:funding-agency>
            <xocs:funding-agency-id>http://data.elsevier.com/vocabulary/SciValFunders/501100001809</xocs:funding-agency-id>
            <xocs:funding-agency-country>http://sws.geonames.org/1814991</xocs:funding-agency-country>
         </xocs:funding>
         <xocs:funding>
            <xocs:funding-agency>Shanghai Municipal Education Commission</xocs:funding-agency>
            <xocs:funding-agency-id>http://data.elsevier.com/vocabulary/SciValFunders/501100003395</xocs:funding-agency-id>
            <xocs:funding-agency-country>http://sws.geonames.org/1814991</xocs:funding-agency-country>
         </xocs:funding>
      </xocs:funding-list>
      <xocs:attachment-metadata-doc>
         <xocs:attachment-set-type>item</xocs:attachment-set-type>
         <xocs:pii-formatted>S0223-5234(20)30399-8</xocs:pii-formatted>
         <xocs:pii-unformatted>S0223523420303998</xocs:pii-unformatted>
         <xocs:eid>1-s2.0-S0223523420303998</xocs:eid>
         <xocs:doi>10.1016/j.ejmech.2020.112428</xocs:doi>
         <xocs:cid>271932</xocs:cid>
         <xocs:timestamp>2021-02-19T22:08:34.091246Z</xocs:timestamp>
         <xocs:cover-date-start>2020-09-01</xocs:cover-date-start>
         <xocs:attachments>
            <xocs:web-pdf>
               <xocs:attachment-eid>1-s2.0-S0223523420303998-main.pdf</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303998/MAIN/application/pdf/cbdc749a95e5349587ef447da1e7531d/main.pdf</xocs:ucs-locator>
               <xocs:filename>main.pdf</xocs:filename>
               <xocs:extension>pdf</xocs:extension>
               <xocs:pdf-optimized>true</xocs:pdf-optimized>
               <xocs:filesize>2886191</xocs:filesize>
               <xocs:web-pdf-purpose>MAIN</xocs:web-pdf-purpose>
               <xocs:web-pdf-page-count>12</xocs:web-pdf-page-count>
               <xocs:web-pdf-images>
                  <xocs:web-pdf-image>
                     <xocs:attachment-eid>1-s2.0-S0223523420303998-main_1.png</xocs:attachment-eid>
                     <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303998/PREVIEW/image/png/1f9829a202e8d6fc573e8332d43b6880/main_1.png</xocs:ucs-locator>
                     <xocs:filename>main_1.png</xocs:filename>
                     <xocs:extension>png</xocs:extension>
                     <xocs:filesize>59009</xocs:filesize>
                     <xocs:pixel-height>849</xocs:pixel-height>
                     <xocs:pixel-width>656</xocs:pixel-width>
                     <xocs:attachment-type>IMAGE-WEB-PDF</xocs:attachment-type>
                     <xocs:pdf-page-num>1</xocs:pdf-page-num>
                  </xocs:web-pdf-image>
               </xocs:web-pdf-images>
            </xocs:web-pdf>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303998-sc1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303998/sc1/DOWNSAMPLED/image/jpeg/5b77954a5c45b290b2fd0d9fa09f0786/sc1.jpg</xocs:ucs-locator>
               <xocs:file-basename>sc1</xocs:file-basename>
               <xocs:filename>sc1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>10913</xocs:filesize>
               <xocs:pixel-height>75</xocs:pixel-height>
               <xocs:pixel-width>556</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303998-gr6.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303998/gr6/DOWNSAMPLED/image/jpeg/20140e7df8be38ac1f0a2e2feceadb5a/gr6.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr6</xocs:file-basename>
               <xocs:filename>gr6.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>34206</xocs:filesize>
               <xocs:pixel-height>220</xocs:pixel-height>
               <xocs:pixel-width>538</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303998-fx5.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303998/fx5/DOWNSAMPLED/image/jpeg/e53d2a52b6bc320202679406121b5196/fx5.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx5</xocs:file-basename>
               <xocs:filename>fx5.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>885</xocs:filesize>
               <xocs:pixel-height>27</xocs:pixel-height>
               <xocs:pixel-width>35</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303998-fx2.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303998/fx2/DOWNSAMPLED/image/jpeg/7858cc4fe2b9418ba52287d8948db020/fx2.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx2</xocs:file-basename>
               <xocs:filename>fx2.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>4221</xocs:filesize>
               <xocs:pixel-height>83</xocs:pixel-height>
               <xocs:pixel-width>143</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303998-gr9.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303998/gr9/DOWNSAMPLED/image/jpeg/27f5d773cd70bc4d89564e69f6374a6f/gr9.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr9</xocs:file-basename>
               <xocs:filename>gr9.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>45720</xocs:filesize>
               <xocs:pixel-height>340</xocs:pixel-height>
               <xocs:pixel-width>622</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303998-gr2.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303998/gr2/DOWNSAMPLED/image/jpeg/9371cf1cfad42b30e796c2a063918083/gr2.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>34967</xocs:filesize>
               <xocs:pixel-height>181</xocs:pixel-height>
               <xocs:pixel-width>600</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303998-fx3.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303998/fx3/DOWNSAMPLED/image/jpeg/f8b2a60e1f90361a08529a58f2ecb1b8/fx3.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx3</xocs:file-basename>
               <xocs:filename>fx3.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>595</xocs:filesize>
               <xocs:pixel-height>20</xocs:pixel-height>
               <xocs:pixel-width>26</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303998-gr1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303998/gr1/DOWNSAMPLED/image/jpeg/8b3dca301a76745729242916920748bd/gr1.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>37869</xocs:filesize>
               <xocs:pixel-height>253</xocs:pixel-height>
               <xocs:pixel-width>711</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303998-fx1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303998/fx1/DOWNSAMPLED/image/jpeg/9b70f3d31c5bf833cae6fc165732a417/fx1.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx1</xocs:file-basename>
               <xocs:abstract-attachment>true</xocs:abstract-attachment>
               <xocs:filename>fx1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>30801</xocs:filesize>
               <xocs:pixel-height>200</xocs:pixel-height>
               <xocs:pixel-width>494</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303998-gr7.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303998/gr7/DOWNSAMPLED/image/jpeg/16e7f2771458a906b6f6346cd80c87c5/gr7.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr7</xocs:file-basename>
               <xocs:filename>gr7.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>41728</xocs:filesize>
               <xocs:pixel-height>328</xocs:pixel-height>
               <xocs:pixel-width>538</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303998-gr3.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303998/gr3/DOWNSAMPLED/image/jpeg/711c9739c21ee142f00229a13345e016/gr3.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>172304</xocs:filesize>
               <xocs:pixel-height>583</xocs:pixel-height>
               <xocs:pixel-width>667</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303998-fx4.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303998/fx4/DOWNSAMPLED/image/jpeg/57f8e1e10a5a1cb8bf2fa219770c11ef/fx4.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx4</xocs:file-basename>
               <xocs:filename>fx4.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>721</xocs:filesize>
               <xocs:pixel-height>26</xocs:pixel-height>
               <xocs:pixel-width>27</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303998-gr12.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303998/gr12/DOWNSAMPLED/image/jpeg/9dac52ec30ecacc4f12540103ef31ae7/gr12.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr12</xocs:file-basename>
               <xocs:filename>gr12.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>45572</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>538</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303998-gr4.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303998/gr4/DOWNSAMPLED/image/jpeg/f5a9619ecd5ab1e3e1a613d285871844/gr4.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>9818</xocs:filesize>
               <xocs:pixel-height>103</xocs:pixel-height>
               <xocs:pixel-width>387</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303998-gr10.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303998/gr10/DOWNSAMPLED/image/jpeg/6d41dde95a18e39d0a3bba1282e1d672/gr10.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr10</xocs:file-basename>
               <xocs:filename>gr10.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>39494</xocs:filesize>
               <xocs:pixel-height>331</xocs:pixel-height>
               <xocs:pixel-width>538</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303998-gr8.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303998/gr8/DOWNSAMPLED/image/jpeg/a5216dfe788dd38498ae1f24530c0115/gr8.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr8</xocs:file-basename>
               <xocs:filename>gr8.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>57114</xocs:filesize>
               <xocs:pixel-height>387</xocs:pixel-height>
               <xocs:pixel-width>689</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303998-gr11.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303998/gr11/DOWNSAMPLED/image/jpeg/ab3025f1b882d70b5f49aa6e084fccbe/gr11.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr11</xocs:file-basename>
               <xocs:filename>gr11.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>56681</xocs:filesize>
               <xocs:pixel-height>279</xocs:pixel-height>
               <xocs:pixel-width>756</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303998-fx6.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303998/fx6/DOWNSAMPLED/image/jpeg/c5ccce65fb17bec73947e89f2e8996c4/fx6.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx6</xocs:file-basename>
               <xocs:filename>fx6.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1010</xocs:filesize>
               <xocs:pixel-height>34</xocs:pixel-height>
               <xocs:pixel-width>42</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303998-gr5.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303998/gr5/DOWNSAMPLED/image/jpeg/c3c3a0ca5061090d91ad66150d9c333c/gr5.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr5</xocs:file-basename>
               <xocs:filename>gr5.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>27663</xocs:filesize>
               <xocs:pixel-height>195</xocs:pixel-height>
               <xocs:pixel-width>778</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303998-fx7.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303998/fx7/DOWNSAMPLED/image/jpeg/c62d3ae2bdb2c6da39a47805990625cd/fx7.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx7</xocs:file-basename>
               <xocs:filename>fx7.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1088</xocs:filesize>
               <xocs:pixel-height>34</xocs:pixel-height>
               <xocs:pixel-width>42</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303998-sc1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303998/sc1/THUMBNAIL/image/gif/54cef8ac150d571cf9cb4510b32e2a63/sc1.sml</xocs:ucs-locator>
               <xocs:file-basename>sc1</xocs:file-basename>
               <xocs:filename>sc1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2350</xocs:filesize>
               <xocs:pixel-height>30</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303998-gr6.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303998/gr6/THUMBNAIL/image/gif/36217b5cfa49c21a00eff5b62b3c7267/gr6.sml</xocs:ucs-locator>
               <xocs:file-basename>gr6</xocs:file-basename>
               <xocs:filename>gr6.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>7919</xocs:filesize>
               <xocs:pixel-height>90</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303998-fx5.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303998/fx5/THUMBNAIL/image/gif/7d771c808cd721cd9eb085b7252a766e/fx5.sml</xocs:ucs-locator>
               <xocs:file-basename>fx5</xocs:file-basename>
               <xocs:filename>fx5.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2315</xocs:filesize>
               <xocs:pixel-height>120</xocs:pixel-height>
               <xocs:pixel-width>155</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303998-fx2.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303998/fx2/THUMBNAIL/image/gif/f1f1ea4efc25d2758191ffec51973be0/fx2.sml</xocs:ucs-locator>
               <xocs:file-basename>fx2</xocs:file-basename>
               <xocs:filename>fx2.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>4054</xocs:filesize>
               <xocs:pixel-height>127</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303998-gr9.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303998/gr9/THUMBNAIL/image/gif/a8f8a5edecf2e113ab398504e089930d/gr9.sml</xocs:ucs-locator>
               <xocs:file-basename>gr9</xocs:file-basename>
               <xocs:filename>gr9.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>7264</xocs:filesize>
               <xocs:pixel-height>120</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303998-gr2.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303998/gr2/THUMBNAIL/image/gif/73cf44740a3b5d075962fea0bacd2b68/gr2.sml</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>4781</xocs:filesize>
               <xocs:pixel-height>66</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303998-fx3.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303998/fx3/THUMBNAIL/image/gif/a66f4752fd1d8840076c20b04364b478/fx3.sml</xocs:ucs-locator>
               <xocs:file-basename>fx3</xocs:file-basename>
               <xocs:filename>fx3.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>1692</xocs:filesize>
               <xocs:pixel-height>91</xocs:pixel-height>
               <xocs:pixel-width>119</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303998-gr1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303998/gr1/THUMBNAIL/image/gif/07c01e27b98cea360888caf5a3257028/gr1.sml</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>4263</xocs:filesize>
               <xocs:pixel-height>78</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303998-fx1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303998/fx1/THUMBNAIL/image/gif/c96c6ac04032e4593eff2e2bbdc8ac85/fx1.sml</xocs:ucs-locator>
               <xocs:file-basename>fx1</xocs:file-basename>
               <xocs:abstract-attachment>true</xocs:abstract-attachment>
               <xocs:filename>fx1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>6900</xocs:filesize>
               <xocs:pixel-height>89</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303998-gr7.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303998/gr7/THUMBNAIL/image/gif/ffcd44ae00ba8d2aeed6e2170f5064a9/gr7.sml</xocs:ucs-locator>
               <xocs:file-basename>gr7</xocs:file-basename>
               <xocs:filename>gr7.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>9794</xocs:filesize>
               <xocs:pixel-height>134</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303998-gr3.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303998/gr3/THUMBNAIL/image/gif/46d883e97589b6460ad9439b6a832a8b/gr3.sml</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>31121</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>188</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303998-fx4.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303998/fx4/THUMBNAIL/image/gif/0fe54a95c3b21f9db440411449424b4b/fx4.sml</xocs:ucs-locator>
               <xocs:file-basename>fx4</xocs:file-basename>
               <xocs:filename>fx4.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2142</xocs:filesize>
               <xocs:pixel-height>117</xocs:pixel-height>
               <xocs:pixel-width>122</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303998-gr12.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303998/gr12/THUMBNAIL/image/gif/7a709ddf78359ab1834f5f914429b4d5/gr12.sml</xocs:ucs-locator>
               <xocs:file-basename>gr12</xocs:file-basename>
               <xocs:filename>gr12.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>12713</xocs:filesize>
               <xocs:pixel-height>67</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303998-gr4.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303998/gr4/THUMBNAIL/image/gif/e5f050c611fad9b3ba19bd86dd5747f1/gr4.sml</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3977</xocs:filesize>
               <xocs:pixel-height>59</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303998-gr10.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303998/gr10/THUMBNAIL/image/gif/6958b26eebfc60877c9abbb379abaad7/gr10.sml</xocs:ucs-locator>
               <xocs:file-basename>gr10</xocs:file-basename>
               <xocs:filename>gr10.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>10389</xocs:filesize>
               <xocs:pixel-height>135</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303998-gr8.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303998/gr8/THUMBNAIL/image/gif/cb119bd84cc3ee90b3760a2d1e5e6911/gr8.sml</xocs:ucs-locator>
               <xocs:file-basename>gr8</xocs:file-basename>
               <xocs:filename>gr8.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>7688</xocs:filesize>
               <xocs:pixel-height>123</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303998-gr11.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303998/gr11/THUMBNAIL/image/gif/7428fbe41d9fff81536552b4f045ba8c/gr11.sml</xocs:ucs-locator>
               <xocs:file-basename>gr11</xocs:file-basename>
               <xocs:filename>gr11.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>7027</xocs:filesize>
               <xocs:pixel-height>81</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303998-fx6.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303998/fx6/THUMBNAIL/image/gif/b0433c184627cfcdd74479ebed44a554/fx6.sml</xocs:ucs-locator>
               <xocs:file-basename>fx6</xocs:file-basename>
               <xocs:filename>fx6.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2882</xocs:filesize>
               <xocs:pixel-height>152</xocs:pixel-height>
               <xocs:pixel-width>189</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303998-gr5.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303998/gr5/THUMBNAIL/image/gif/08c5e38f8f56f079b60bf731847a0675/gr5.sml</xocs:ucs-locator>
               <xocs:file-basename>gr5</xocs:file-basename>
               <xocs:filename>gr5.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3127</xocs:filesize>
               <xocs:pixel-height>55</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303998-fx7.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303998/fx7/THUMBNAIL/image/gif/e693e44635f1b8e4f7207326dc266c5f/fx7.sml</xocs:ucs-locator>
               <xocs:file-basename>fx7</xocs:file-basename>
               <xocs:filename>fx7.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2863</xocs:filesize>
               <xocs:pixel-height>152</xocs:pixel-height>
               <xocs:pixel-width>188</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303998-sc1_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303998/sc1/HIGHRES/image/jpeg/bffe980385dfd9a05ffe6e6606cc8bc3/sc1_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>sc1</xocs:file-basename>
               <xocs:filename>sc1_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>79629</xocs:filesize>
               <xocs:pixel-height>334</xocs:pixel-height>
               <xocs:pixel-width>2461</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303998-gr6_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303998/gr6/HIGHRES/image/jpeg/5246fe0e3682ded20d9821cbb7318098/gr6_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr6</xocs:file-basename>
               <xocs:filename>gr6_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>236084</xocs:filesize>
               <xocs:pixel-height>976</xocs:pixel-height>
               <xocs:pixel-width>2382</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303998-fx5_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303998/fx5/HIGHRES/image/jpeg/7be7baed5fbaf4120a0313b915a69033/fx5_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx5</xocs:file-basename>
               <xocs:filename>fx5_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>3970</xocs:filesize>
               <xocs:pixel-height>120</xocs:pixel-height>
               <xocs:pixel-width>155</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303998-fx2_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303998/fx2/HIGHRES/image/jpeg/db1ef31850825f2291edfcff6312ea7a/fx2_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx2</xocs:file-basename>
               <xocs:filename>fx2_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>27747</xocs:filesize>
               <xocs:pixel-height>368</xocs:pixel-height>
               <xocs:pixel-width>637</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303998-gr9_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303998/gr9/HIGHRES/image/jpeg/b5fe0b99890d17edf77bacbf284f2259/gr9_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr9</xocs:file-basename>
               <xocs:filename>gr9_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>335286</xocs:filesize>
               <xocs:pixel-height>1508</xocs:pixel-height>
               <xocs:pixel-width>2756</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303998-gr2_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303998/gr2/HIGHRES/image/jpeg/1e9aac357bb66cba0d5a0a9c8916fd79/gr2_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>250988</xocs:filesize>
               <xocs:pixel-height>803</xocs:pixel-height>
               <xocs:pixel-width>2657</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303998-fx3_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303998/fx3/HIGHRES/image/jpeg/b1d09cee1f15da71fa70175ed31b582b/fx3_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx3</xocs:file-basename>
               <xocs:filename>fx3_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>2823</xocs:filesize>
               <xocs:pixel-height>91</xocs:pixel-height>
               <xocs:pixel-width>119</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303998-gr1_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303998/gr1/HIGHRES/image/jpeg/d13979c8f01acb34686410ad9096a6e5/gr1_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>295934</xocs:filesize>
               <xocs:pixel-height>1123</xocs:pixel-height>
               <xocs:pixel-width>3150</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303998-fx1_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303998/fx1/HIGHRES/image/jpeg/b489384d9ade0c2a510698427bebe466/fx1_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx1</xocs:file-basename>
               <xocs:abstract-attachment>true</xocs:abstract-attachment>
               <xocs:filename>fx1_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>198080</xocs:filesize>
               <xocs:pixel-height>886</xocs:pixel-height>
               <xocs:pixel-width>2186</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303998-gr7_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303998/gr7/HIGHRES/image/jpeg/dcdb8291c9340b9c59562baf02080260/gr7_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr7</xocs:file-basename>
               <xocs:filename>gr7_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>618472</xocs:filesize>
               <xocs:pixel-height>1453</xocs:pixel-height>
               <xocs:pixel-width>2382</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303998-gr3_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303998/gr3/HIGHRES/image/jpeg/c00ed0de0a47ad746311ce733cb1d632/gr3_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1419232</xocs:filesize>
               <xocs:pixel-height>2579</xocs:pixel-height>
               <xocs:pixel-width>2953</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303998-fx4_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303998/fx4/HIGHRES/image/jpeg/aa0c82ac3626b6cd7a0842e029b3c7d5/fx4_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx4</xocs:file-basename>
               <xocs:filename>fx4_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>3548</xocs:filesize>
               <xocs:pixel-height>117</xocs:pixel-height>
               <xocs:pixel-width>122</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303998-gr12_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303998/gr12/HIGHRES/image/jpeg/3516fd0bf857085c949af8ba954f1c91/gr12_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr12</xocs:file-basename>
               <xocs:filename>gr12_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>363437</xocs:filesize>
               <xocs:pixel-height>724</xocs:pixel-height>
               <xocs:pixel-width>2382</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303998-gr4_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303998/gr4/HIGHRES/image/jpeg/41536c00d564f5439ca9765129b8abb4/gr4_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>78597</xocs:filesize>
               <xocs:pixel-height>458</xocs:pixel-height>
               <xocs:pixel-width>1714</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303998-gr10_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303998/gr10/HIGHRES/image/jpeg/84309ff434c020c8b25fec4bc1d51bbb/gr10_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr10</xocs:file-basename>
               <xocs:filename>gr10_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>279986</xocs:filesize>
               <xocs:pixel-height>1466</xocs:pixel-height>
               <xocs:pixel-width>2382</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303998-gr8_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303998/gr8/HIGHRES/image/jpeg/5824fa947a02e8c3ee004528d5af75c1/gr8_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr8</xocs:file-basename>
               <xocs:filename>gr8_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>433701</xocs:filesize>
               <xocs:pixel-height>1712</xocs:pixel-height>
               <xocs:pixel-width>3051</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303998-gr11_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303998/gr11/HIGHRES/image/jpeg/9206e899dc13db8b7c91098bf29c0cf9/gr11_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr11</xocs:file-basename>
               <xocs:filename>gr11_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>542235</xocs:filesize>
               <xocs:pixel-height>1233</xocs:pixel-height>
               <xocs:pixel-width>3346</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303998-fx6_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303998/fx6/HIGHRES/image/jpeg/913076acb4f90a76198e32bc59fca3d1/fx6_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx6</xocs:file-basename>
               <xocs:filename>fx6_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>4957</xocs:filesize>
               <xocs:pixel-height>152</xocs:pixel-height>
               <xocs:pixel-width>189</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303998-gr5_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303998/gr5/HIGHRES/image/jpeg/ea7cac1e63d8464b0a20faefb9d5fc23/gr5_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr5</xocs:file-basename>
               <xocs:filename>gr5_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>170563</xocs:filesize>
               <xocs:pixel-height>864</xocs:pixel-height>
               <xocs:pixel-width>3444</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303998-fx7_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303998/fx7/HIGHRES/image/jpeg/11db478b7ac6968a18fae940718d85f1/fx7_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx7</xocs:file-basename>
               <xocs:filename>fx7_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>5087</xocs:filesize>
               <xocs:pixel-height>152</xocs:pixel-height>
               <xocs:pixel-width>188</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303998-mmc1.pdf</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303998/mmc1/MAIN/application/pdf/9375f7e4df91f8e13d71c3ca47f0e3ca/mmc1.pdf</xocs:ucs-locator>
               <xocs:file-basename>mmc1</xocs:file-basename>
               <xocs:filename>mmc1.pdf</xocs:filename>
               <xocs:extension>pdf</xocs:extension>
               <xocs:pdf-optimized>false</xocs:pdf-optimized>
               <xocs:filesize>2656075</xocs:filesize>
               <xocs:attachment-type>APPLICATION</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303998-am.pdf</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/egi:10DG81SVN7C/MAIN/application/pdf/673ceee266b4c838e24e5a2c8c498b0f/am.pdf</xocs:ucs-locator>
               <xocs:file-basename>am</xocs:file-basename>
               <xocs:filename>am.pdf</xocs:filename>
               <xocs:extension>pdf</xocs:extension>
               <xocs:pdf-optimized>false</xocs:pdf-optimized>
               <xocs:filesize>1158033</xocs:filesize>
               <xocs:attachment-type>AAM-PDF</xocs:attachment-type>
            </xocs:attachment>
         </xocs:attachments>
      </xocs:attachment-metadata-doc>
   </xocs:meta><xocs:serial-item xmlns:xoe="http://www.elsevier.com/xml/xoe/dtd">
      <article xmlns="http://www.elsevier.com/xml/ja/dtd" docsubtype="fla" version="5.6" xml:lang="en">
         <item-info>
            <jid>EJMECH</jid>
            <aid>112428</aid>
            <ce:article-number>112428</ce:article-number>
            <ce:pii>S0223-5234(20)30399-8</ce:pii>
            <ce:doi>10.1016/j.ejmech.2020.112428</ce:doi>
            <ce:copyright type="full-transfer" year="2020">Elsevier Masson SAS</ce:copyright>
         </item-info>
         <ce:floats>
            <ce:figure id="fig1">
               <ce:label>Fig. 1</ce:label>
               <ce:caption id="cap0010">
                  <ce:simple-para id="fspara0010" view="all">Representative of known STAT3 inhibitors.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0020" role="short">Fig. 1</ce:alt-text>
               <ce:link locator="gr1" xlink:href="pii:S0223523420303998/gr1" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig2">
               <ce:label>Fig. 2</ce:label>
               <ce:caption id="cap0015">
                  <ce:simple-para id="fspara0015" view="all">Previous and our structure-based drug design of STAT3 inhibitors based on BBI608.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0025" role="short">Fig. 2</ce:alt-text>
               <ce:link locator="gr2" xlink:href="pii:S0223523420303998/gr2" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig3">
               <ce:label>Fig. 3</ce:label>
               <ce:caption id="cap0020">
                  <ce:simple-para id="fspara0020" view="all">Docking modes of BBI608 and designed compounds <ce:bold>A1</ce:bold>−<ce:bold>A5</ce:bold>.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0030" role="short">Fig. 3</ce:alt-text>
               <ce:link locator="gr3" xlink:href="pii:S0223523420303998/gr3" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig4">
               <ce:label>Fig. 4</ce:label>
               <ce:caption id="cap0025">
                  <ce:simple-para id="fspara0025" view="all">X-ray crystallography of a representative compound <ce:bold>A24</ce:bold>.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0035" role="short">Fig. 4</ce:alt-text>
               <ce:link locator="gr4" xlink:href="pii:S0223523420303998/gr4" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig5">
               <ce:label>Fig. 5</ce:label>
               <ce:caption id="cap0030">
                  <ce:simple-para id="fspara0030" view="all">(A) Binding of the fluorescent probes 5-FAM-GpYLPQTV-NH<ce:inf loc="post">2</ce:inf> to STAT3 SH2 domain. The probe was incubated at 10 nM with increasing amounts of STAT3 protein. (B) Dose−response competitive binding curve of compounds <ce:bold>A6</ce:bold> and <ce:bold>A11</ce:bold> to STAT3 using the FP-based binding assay.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0040" role="short">Fig. 5</ce:alt-text>
               <ce:link locator="gr5" xlink:href="pii:S0223523420303998/gr5" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig6">
               <ce:label>Fig. 6</ce:label>
               <ce:caption id="cap0035">
                  <ce:simple-para id="fspara0035" view="all">Western blot analysis of the inhibition of STAT3-Y705 phosphorylation, the selective inhibition against STAT1 and the downstream target proteins (C-Myc and Cyclin D1) by compound <ce:bold>A11</ce:bold> in the MDA-MB-231 cell line. Cells were treated with <ce:bold>A11 or A6</ce:bold> for 24 h, and levels of STAT3, pSTAT3, STAT1, p-STAT1, C-Myc and Cyclin D1 were probed by specific antibodies. GAPDH was used as the loading control.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0045" role="short">Fig. 6</ce:alt-text>
               <ce:link locator="gr6" xlink:href="pii:S0223523420303998/gr6" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig7">
               <ce:label>Fig. 7</ce:label>
               <ce:caption id="cap0040">
                  <ce:simple-para id="fspara0040" view="all">MDA-MB-231 cells were incubated with 3.0 μM <ce:bold>A11</ce:bold> for 24 h and stained with anti-phospho-STAT3 (p-STAT3) and Hoechst before subjected to analysis. Red: p-STAT3; blue: nucleus (Scale bar: 10 μm). (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0050" role="short">Fig. 7</ce:alt-text>
               <ce:link locator="gr7" xlink:href="pii:S0223523420303998/gr7" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig8">
               <ce:label>Fig. 8</ce:label>
               <ce:caption id="cap0045">
                  <ce:simple-para id="fspara0045" view="all">Flow cytometric analysis of the apoptotic effect of compound <ce:bold>A11</ce:bold> in MDA-MB-231 cells through Annexin-V-FITC/PI staining assay. (A) MDA-MB-231 cells were treated with compound <ce:bold>A11</ce:bold> at tested concentrations for 24 h. (B) The histograms for apoptosis rate (early and late stages of apoptosis). Data are the mean ± SD of three independent experiments. ∗∗∗, p < 0.001, ∗∗, p < 0.01.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0055" role="short">Fig. 8</ce:alt-text>
               <ce:link locator="gr8" xlink:href="pii:S0223523420303998/gr8" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig9">
               <ce:label>Fig. 9</ce:label>
               <ce:caption id="cap0050">
                  <ce:simple-para id="fspara0050" view="all">Cell cycle analysis of compound <ce:bold>A11</ce:bold> by flow cytometry. MDA-MB-231 cells were treated with increasing concentrations of compound <ce:bold>A11</ce:bold> for 24 h.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0060" role="short">Fig. 9</ce:alt-text>
               <ce:link locator="gr9" xlink:href="pii:S0223523420303998/gr9" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig10">
               <ce:label>Fig. 10</ce:label>
               <ce:caption id="cap0055">
                  <ce:simple-para id="fspara0055" view="all">Compound <ce:bold>A11</ce:bold> inhibited the growth of human xenograft tumor <ce:italic>in vivo</ce:italic>. MDA-MB-231 xenograft mouse models were treated with <ce:bold>A11</ce:bold> or vehicle control daily at indicated dosages for 21 consecutive days. (A) Anatomical nude mice’s tumor tissues untreated or treated with <ce:bold>A11</ce:bold>. (B) The tumor volume and the tumor growth inhibition values (TGI<ce:inf loc="post">TV</ce:inf>) were measured on the final day of the study. (C) The tumor weight and the tumor growth inhibition values (TGI<ce:inf loc="post">TW</ce:inf>) were measured on the final day of the study. (D) The growing curves of mice’s body weight. Data are shown as mean ± SEM, n = 6; ∗, P < 0.05.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0065" role="short">Fig. 10</ce:alt-text>
               <ce:link locator="gr10" xlink:href="pii:S0223523420303998/gr10" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig11">
               <ce:label>Fig. 11</ce:label>
               <ce:caption id="cap0060">
                  <ce:simple-para id="fspara0060" view="all">Immunofluorescent assay revealed that <ce:bold>A11</ce:bold> inhibited the levels of p-STAT3 in tumor tissues. Data are shown as mean ± SEM, n = 4; ∗∗, p < 0.01 (Scale bar: 50 μm).</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0070" role="short">Fig. 11</ce:alt-text>
               <ce:link locator="gr11" xlink:href="pii:S0223523420303998/gr11" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig12">
               <ce:label>Fig. 12</ce:label>
               <ce:caption id="cap0065">
                  <ce:simple-para id="fspara0065" view="all">Molecular modeling study of <ce:bold>A11</ce:bold> in STAT3 SH2 domain (PDB code: <ce:inter-ref id="intref0045" xlink:href="pdb:1BG1" xlink:type="simple">1BG1</ce:inter-ref>). (A) Superimposed pose of <ce:bold>A11</ce:bold> (green) and BBI606 (pink) bound in the surface of binding site. (B) Predicted interaction of <ce:bold>A11</ce:bold> (green) within STAT3 SH2 domain. The figures were generated using Pymol. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0075" role="short">Fig. 12</ce:alt-text>
               <ce:link locator="gr12" xlink:href="pii:S0223523420303998/gr12" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="sch1">
               <ce:label>Scheme 1</ce:label>
               <ce:caption id="cap0070">
                  <ce:simple-para id="fspara0070" view="all">Synthesis of Compounds <ce:bold>A1</ce:bold>, <ce:bold>A6</ce:bold>-<ce:bold>A30.</ce:bold>
                  </ce:simple-para>
                  <ce:simple-para id="fspara0075" view="all">Regents and conditions: (a) Br<ce:inf loc="post">2</ce:inf>, AlCl<ce:inf loc="post">3</ce:inf>, CH<ce:inf loc="post">2</ce:inf>Cl<ce:inf loc="post">2</ce:inf>, 40 °C; (b) CrO<ce:inf loc="post">3</ce:inf>, CH<ce:inf loc="post">3</ce:inf>COOH, 60 °C; (c) Pd(OAc)<ce:inf loc="post">2</ce:inf>, BINAP, Cs<ce:inf loc="post">2</ce:inf>CO<ce:inf loc="post">3</ce:inf>, Toluene, 120 °C.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0080" role="short">Scheme 1</ce:alt-text>
               <ce:link locator="sc1" xlink:href="pii:S0223523420303998/sc1" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" colsep="0" frame="topbot" id="tbl1" rowsep="0">
               <ce:label>Table 1</ce:label>
               <ce:caption id="cap0075">
                  <ce:simple-para id="tspara0010" view="all">Antiproliferative activity of the designed compounds.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0085" role="short">Table 1</ce:alt-text>
               <ce:link locator="fx2" xlink:href="pii:S0223523420303998/fx2" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
               <tgroup cols="5">
                  <colspec colname="col1" colnum="1"/></colspec>
                  <colspec colname="col2" colnum="2"/></colspec>
                  <colspec colname="col3" colnum="3"/></colspec>
                  <colspec colname="col4" colnum="4"/></colspec>
                  <colspec colname="col5" colnum="5"/></colspec>
                  <thead>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1" role="rowgroup">Compd.</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1" role="rowgroup">R</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" nameend="col5" namest="col3" role="colgroup">IC50 ± SD (μM) a</entry>
                     </row>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">MDA-MB-231</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">MDA-MB-468</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">HepG2</entry>
                     </row>
                  </thead>
                  <tbody>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>A1</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-Ph</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.14 ± 0.16</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.03 ± 0.06</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.54 ± 0.24</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>A6</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2-CH<inf loc="post">3</inf>-Ph</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.56 ± 0.10</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.73 ± 0.04</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.21 ± 0.01</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>A7</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3-CH<inf loc="post">3</inf>-Ph</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2.62 ± 0.10</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4.54 ± 0.17</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">5.50 ± 0.20</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>A8</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4-CH<inf loc="post">3</inf>-Ph</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.90 ± 0.08</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3.12 ± 0.02</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.85 ± 0.07</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>A9</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2-OCH<inf loc="post">3</inf>-Ph</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.92 ± 0.08</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.05 ± 0.11</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2.41 ± 0.33</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>A10</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3-OCH<inf loc="post">3</inf>-Ph</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.48 ± 0.06</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.55 ± 0.05</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2.36 ± 0.33</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>A11</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4-OCH<inf loc="post">3</inf>-Ph</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.67 ± 0.02</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.77 ± 0.01</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.24 ± 0.16</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>A12</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2-F-Ph</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2.34 ± 0.19</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2.00 ± 0.25</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2.55 ± 0.10</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>A13</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3-F-Ph</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3.50 ± 0.18</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2.50 ± 0.43</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">5.34 ± 0.45</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>A14</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4-F-Ph</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3.21 ± 0.10</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">7.77 ± 0.32</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">8.01 ± 0.11</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>A15</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2-CF<inf loc="post">3</inf>-Ph</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3.12 ± 0.23</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.75 ± 0.12</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4.04 ± 0.21</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>A16</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3-CF<inf loc="post">3</inf>-Ph</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.51 ± 0.17</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.16 ± 0.17</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.99 ± 0.06</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>A17</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4-CF<inf loc="post">3</inf>-Ph</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3.70 ± 0.30</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2.27 ± 0.50</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">6.17 ± 0.13</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>A18</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2-C<inf loc="post">2</inf>H<inf loc="post">5</inf>-Ph</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2.00 ± 0.25</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2.46 ± 0.02</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3.38 ± 0.52</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>A19</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4-N(CH<inf loc="post">3</inf>)<inf loc="post">2</inf>-Ph</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.53 ± 0.03</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.83 ± 0.24</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.51 ± 0.12</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>A20</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4-isopropoxy-Ph</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.11 ± 0.19</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.18 ± 0.25</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.04 ± 0.18</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>A21</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2-CH<inf loc="post">3</inf>,4-OCH<inf loc="post">3</inf>-Ph</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2.46 ± 0.28</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2.92 ± 0.05</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">5.90 ± 0.26</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>A22</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2-CH<inf loc="post">3</inf>,6-CH<inf loc="post">3</inf>-Ph</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.88 ± 0.05</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3.3 ± 0.14</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">8.03 ± 0.41</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>A23</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2-CH<inf loc="post">3</inf>,4-OCH<inf loc="post">3</inf>,6-CH<inf loc="post">3</inf>-Ph</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.67 ± 0.02</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.53 ± 1.22</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2.01 ± 0.02</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>A24</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3-CH<inf loc="post">3</inf>,4-CH<inf loc="post">3</inf>-Ph</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2.54 ± 0.28</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.85 ± 0.02</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">8.12 ± 0.40</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>A25</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3-CH<inf loc="post">3</inf>,5-F-Ph</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2.62 ± 0.37</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2.11 ± 0.26</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">5.66 ± 0.46</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>A26</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx3" xlink:href="pii:S0223523420303998/fx3" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0090" role="short">Image 3</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.94 ± 0.09</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.97 ± 0.16</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.83 ± 0.03</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>A27</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx4" xlink:href="pii:S0223523420303998/fx4" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0095" role="short">Image 4</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4.87 ± 0.20</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">8.84 ± 0.64</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">6.75 ± 0.06</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>A28</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx5" xlink:href="pii:S0223523420303998/fx5" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0100" role="short">Image 5</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.23 ± 0.03</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2.47 ± 0.11</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">7.17 ± 0.37</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>A29</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx6" xlink:href="pii:S0223523420303998/fx6" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0105" role="short">Image 6</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2.88 ± 0.07</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4.13 ± 0.44</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">6.55 ± 0.18</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>A30</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx7" xlink:href="pii:S0223523420303998/fx7" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0110" role="short">Image 7</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2.07 ± 0.28</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3.23 ± 0.06</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">6.80 ± 0.17</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">BBI608</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.70 ± 0.06</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.14 ± 0.04</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.84 ± 0.03</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Stattic</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2.64 ± 0.03</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.92 ± 0.08</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ND</entry>
                     </row>
                  </tbody>
               </tgroup>
               <ce:legend>
                  <ce:simple-para id="tspara0015" view="all">
                     <ce:sup loc="post">a</ce:sup> The inhibitory effects of these compounds on the proliferation of cancer cell lines were determined by the CCK8 assay. The data are the mean ± SD from at least three independent experiments.</ce:simple-para>
               </ce:legend>
            </ce:table>
         </ce:floats>
         <head>
            <ce:dochead id="dhead0010">
               <ce:textfn>Research paper</ce:textfn>
            </ce:dochead>
            <ce:title id="title0010">Design, synthesis and biological evaluation of novel potent STAT3 inhibitors based on BBI608 for cancer therapy</ce:title>
            <ce:author-group id="augrp0010">
               <ce:author id="au1" author-id="S0223523420303998-e95edf8f49f1cd55b420a22a6f567885">
                  <ce:given-name>Kai-Rui</ce:given-name>
                  <ce:surname>Feng</ce:surname>
                  <ce:cross-ref id="crosref0010" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crosref0015" refid="fn1">
                     <ce:sup loc="post">1</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au2" author-id="S0223523420303998-1e0e9a8bbf6f65797ca6bff1bda76e07">
                  <ce:given-name>Feng</ce:given-name>
                  <ce:surname>Wang</ce:surname>
                  <ce:cross-ref id="crosref0020" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crosref0025" refid="fn1">
                     <ce:sup loc="post">1</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au3" author-id="S0223523420303998-5a686da8def307101bac4b2f4cc2568a">
                  <ce:given-name>Xin-Wei</ce:given-name>
                  <ce:surname>Shi</ce:surname>
                  <ce:cross-ref id="crosref0030" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au4" author-id="S0223523420303998-9d5c9a46b51ebbb02f7dd72a29c31a6e">
                  <ce:given-name>Yun-Xuan</ce:given-name>
                  <ce:surname>Tan</ce:surname>
                  <ce:cross-ref id="crosref0035" refid="aff2">
                     <ce:sup loc="post">b</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au5" author-id="S0223523420303998-a702ddf4638f6e75a34c1e06fca998c0">
                  <ce:given-name>Jia-Ying</ce:given-name>
                  <ce:surname>Zhao</ce:surname>
                  <ce:cross-ref id="crosref0040" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au6" author-id="S0223523420303998-59b07913266290748b097e72cdcba436">
                  <ce:given-name>Jian-Wei</ce:given-name>
                  <ce:surname>Zhang</ce:surname>
                  <ce:cross-ref id="crosref0045" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au7" author-id="S0223523420303998-78e0c72c4dbe1f937abf5ba79b635322">
                  <ce:given-name>Qing-Hua</ce:given-name>
                  <ce:surname>Li</ce:surname>
                  <ce:cross-ref id="crosref0050" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crosref0055" refid="cor2">
                     <ce:sup loc="post">∗∗</ce:sup>
                  </ce:cross-ref>
                  
               </ce:author>
               <ce:author id="au8" author-id="S0223523420303998-cca0ecb3d3d284e01432fa06bb2d07e7">
                  <ce:given-name>Guo-Qiang</ce:given-name>
                  <ce:surname>Lin</ce:surname>
                  <ce:cross-ref id="crosref0060" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crosref0065" refid="aff2">
                     <ce:sup loc="post">b</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au9" author-id="S0223523420303998-227fe214ecb13918ac46add9dc4fd2f3">
                  <ce:given-name>Dingding</ce:given-name>
                  <ce:surname>Gao</ce:surname>
                  <ce:cross-ref id="crosref0070" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crosref0075" refid="cor3">
                     <ce:sup loc="post">∗∗∗</ce:sup>
                  </ce:cross-ref>
                  
               </ce:author>
               <ce:author id="au10" author-id="S0223523420303998-caf77a5a6a3dd6ae08022ba3161a5a62">
                  <ce:given-name>Ping</ce:given-name>
                  <ce:surname>Tian</ce:surname>
                  <ce:cross-ref id="crosref0080" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crosref0085" refid="aff2">
                     <ce:sup loc="post">b</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crosref0090" refid="cor1">
                     <ce:sup loc="post">∗</ce:sup>
                  </ce:cross-ref>
                  
               </ce:author>
               <ce:affiliation id="aff1" affiliation-id="S0223523420303998-6df0a9f09f1f8bab17726ee147994664">
                  <ce:label>a</ce:label>
                  <ce:textfn>The Research Center of Chiral Drugs, Innovation Research Institute of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>The Research Center of Chiral Drugs</sa:organization>
                     <sa:organization>Innovation Research Institute of Traditional Chinese Medicine</sa:organization>
                     <sa:organization>Shanghai University of Traditional Chinese Medicine</sa:organization>
                     <sa:city>Shanghai</sa:city>
                     <sa:postal-code>201203</sa:postal-code>
                     <sa:country>China</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="srct0010">The Research Center of Chiral Drugs, Innovation Research Institute of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China</ce:source-text>
               </ce:affiliation>
               <ce:affiliation id="aff2" affiliation-id="S0223523420303998-4f3f0bc6cd1e01d42d015f18b29fb37f">
                  <ce:label>b</ce:label>
                  <ce:textfn>CAS Key Laboratory of Synthetic Chemistry of Natural Substances, Center for Excellence in Molecular Synthesis, Shanghai Institute of Organic Chemistry, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, 200032, China</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>CAS Key Laboratory of Synthetic Chemistry of Natural Substances</sa:organization>
                     <sa:organization>Center for Excellence in Molecular Synthesis</sa:organization>
                     <sa:organization>Shanghai Institute of Organic Chemistry</sa:organization>
                     <sa:organization>University of Chinese Academy of Sciences</sa:organization>
                     <sa:organization>Chinese Academy of Sciences</sa:organization>
                     <sa:city>Shanghai</sa:city>
                     <sa:postal-code>200032</sa:postal-code>
                     <sa:country>China</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="srct0015">CAS Key Laboratory of Synthetic Chemistry of Natural Substances, Center for Excellence in Molecular Synthesis, Shanghai Institute of Organic Chemistry, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, 200032, China</ce:source-text>
               </ce:affiliation>
               <ce:correspondence id="cor1">
                  <ce:label>∗</ce:label>
                  <ce:text>Corresponding author. The Research Center of Chiral Drugs, Innovation Research Institute of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.</ce:text>
                  <sa:affiliation>
                     <sa:organization>The Research Center of Chiral Drugs</sa:organization>
                     <sa:organization>Innovation Research Institute of Traditional Chinese Medicine</sa:organization>
                     <sa:organization>Shanghai University of Traditional Chinese Medicine</sa:organization>
                     <sa:city>Shanghai</sa:city>
                     <sa:postal-code>201203</sa:postal-code>
                     <sa:country>China</sa:country>
                  </sa:affiliation>
               </ce:correspondence>
               <ce:correspondence id="cor2">
                  <ce:label>∗∗</ce:label>
                  <ce:text>Corresponding author.</ce:text>
               </ce:correspondence>
               <ce:correspondence id="cor3">
                  <ce:label>∗∗∗</ce:label>
                  <ce:text>Corresponding author.</ce:text>
               </ce:correspondence>
               <ce:footnote id="fn1">
                  <ce:label>1</ce:label>
                  <ce:note-para id="ntpara0010" view="all">These authors contributed equally to this work.</ce:note-para>
               </ce:footnote>
            </ce:author-group>
            <ce:date-received day="17" month="1" year="2020"/></ce:date-received>
            <ce:date-revised day="24" month="4" year="2020"/></ce:date-revised>
            <ce:date-accepted day="5" month="5" year="2020"/></ce:date-accepted>
            <ce:abstract id="abs0010" xml:lang="en" view="all" class="author"><ce:abstract-sec id="abssec0010" view="all">
                  <ce:simple-para id="abspara0010" view="all">Persistently activated signal transducer and activator of transcription 3 (STAT3) plays an important role in the development of multiple cancers, and therefore is a potential therapeutic target for cancer prevention. Herein, we report the rational design, synthesis, and biological evaluation of novel potent STAT3 inhibitors based on BBI608. Among them, compound <ce:bold>A11</ce:bold> exhibited the most potent <ce:italic>in vitro</ce:italic> tumor cell growth inhibitory activities toward MDA-MB-231, MDA-MB-468 and HepG2 cells with IC<ce:inf loc="post">50</ce:inf> values as low as 0.67 ± 0.02 μM, 0.77 ± 0.01 μM and 1.24 ± 0.16 μM, respectively. Fluorescence polarization (FP) assay validated the binding of compound <ce:bold>A11</ce:bold> in STAT3 SH2 domain with the IC<ce:inf loc="post">50</ce:inf> value of 5.18 μM. Further mechanistic studies indicated that <ce:bold>A11</ce:bold> inhibited the activation of STAT3 (Y705), and thus reduced the expression of STAT3 downstream genes CyclinD1 and C-Myc. Simultaneously, it induced cancer cell S phase arrest and apoptosis in a concentration-dependent manner. An additional <ce:italic>in vivo</ce:italic> study revealed that <ce:bold>A11</ce:bold> suppressed the MDA-MB-231 xenograft tumor growth in mice at the dose of 10 mg/kg (i.p.) without obvious body-weight loss. Finally, molecular docking study further elucidated the binding mode of <ce:bold>A11</ce:bold> in STAT3 SH2 domain.</ce:simple-para>
               </ce:abstract-sec></ce:abstract>
            <ce:abstract class="graphical" id="abs0015" view="all">
               <ce:section-title id="sectitle0015">Graphical abstract</ce:section-title>
               <ce:abstract-sec id="abssec0015" view="all">
                  <ce:simple-para id="abspara0015" view="all">
                     <ce:display>
                        <ce:figure id="undfig1">
                           <ce:alt-text id="alttext0010" role="short">Image 1</ce:alt-text>
                           <ce:link locator="fx1" xlink:href="pii:S0223523420303998/fx1" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
                        </ce:figure>
                     </ce:display>
                  </ce:simple-para>
               </ce:abstract-sec>
            </ce:abstract>
            
            <ce:keywords id="kwrds0010" xml:lang="en" view="all" class="keyword">
               <ce:section-title id="sectitle0025">Keywords</ce:section-title>
               <ce:keyword id="kwrd0010">
                  <ce:text>STAT3 inhibitors</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0015">
                  <ce:text>BBI608</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0020">
                  <ce:text>Anti-tumor activity</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0025">
                  <ce:text>Molecular docking</ce:text>
               </ce:keyword>
            </ce:keywords>
         </head>
         <body view="all">
            <ce:sections>
               <ce:section id="sec1" role="introduction" view="all">
                  <ce:label>1</ce:label>
                  <ce:section-title id="sectitle0030">Introduction</ce:section-title>
                  <ce:para id="p0030" view="all">Signal transducer and activator of transcription 3 (STAT3) is a member of the STAT family and play a pivotal role in tumor initiation, progression and maintenance [<ce:cross-refs id="crosrefs0010" refid="bib1 bib2 bib3 bib4">1–4</ce:cross-refs>]. Once upon activated by upstream kinases (growth factor receptors, tyrosine kinases, Janus kinases, Src family kinases, etc.), STAT3 monomers are phosphorylated at specific tyrosine residues (Y705) in the C-terminal domain and form transcriptionally active homodimers in a symmetric reciprocal manner. Then these homodimers translocate into the nucleus and bind to a specific DNA sequence, regulating target genes transcription [<ce:cross-refs id="crosrefs0015" refid="bib5 bib6 bib7">5–7</ce:cross-refs>]. Abnormally activated STAT3 signaling is found in a variety of solid tumors and hematological malignancies, and can induce tumor angiogenesis and suppresses anti-tumor immune responses [<ce:cross-refs id="crosrefs0020" refid="bib8 bib9 bib10 bib11">8–11</ce:cross-refs>]. In addition, aberrant STAT3 correlates with resistance to chemotherapy and poor prognosis [<ce:cross-ref id="crosref0095" refid="bib12">12</ce:cross-ref>,<ce:cross-ref id="crosref0100" refid="bib13">13</ce:cross-ref>]. Abundant evidence suggests that STAT3 is an ideal target for cancer therapy, and various small inhibitors were identified using multiple approaches [<ce:cross-ref id="crosref0105" refid="bib14">14</ce:cross-ref>], such as STA-21 [<ce:cross-ref id="crosref0110" refid="bib15">15</ce:cross-ref>], LLL-12 [<ce:cross-ref id="crosref0115" refid="bib16">16</ce:cross-ref>], LY-5 [<ce:cross-ref id="crosref0120" refid="bib17">17</ce:cross-ref>], Stattic [<ce:cross-ref id="crosref0125" refid="bib18">18</ce:cross-ref>], Niclosamide [<ce:cross-ref id="crosref0130" refid="bib19">19</ce:cross-ref>], S3I-201 [<ce:cross-ref id="crosref0135" refid="bib20">20</ce:cross-ref>], S3I-201-1066 [<ce:cross-ref id="crosref0140" refid="bib21">21</ce:cross-ref>], <ce:bold>8</ce:bold> [<ce:cross-ref id="crosref0145" refid="bib22">22</ce:cross-ref>], BBI608 [<ce:cross-ref id="crosref0150" refid="bib23">23</ce:cross-ref>], and other representative STAT3 inhibitors [<ce:cross-refs id="crosrefs0025" refid="bib24 bib25 bib26 bib27 bib28 bib29 bib30 bib31">24–31</ce:cross-refs>] (see <ce:cross-ref id="optOnHkRcaeaR" refid="fig1">Fig. 1</ce:cross-ref>
                     <ce:float-anchor refid="fig1"/></ce:float-anchor>). It is worth noting that Wang and co-workers have recently reported some potent, selective, and efficacious small-molecule STAT3 degraders based upon the proteolysis targeting chimera (PROTAC) concept [<ce:cross-ref id="crosref0155" refid="bib32">32</ce:cross-ref>,<ce:cross-ref id="crosref0160" refid="bib33">33</ce:cross-ref>]. However, there has been no STAT3-targeting drug approved by the FDA to date. This may be partly due to the lack of understanding of signaling crosstalk and adverse events related to STAT3-specific activity in normal tissues. Also, the scarcity of membrane permeability and stability, and weak binding affinity were found to be the main roadblocks of these inhibitors [<ce:cross-refs id="crosrefs0030" refid="bib34 bib35 bib36">34–36</ce:cross-refs>]. Consequently, development of novel potent STAT3 inhibitors will bring enormous challenges and opportunities in the cancer prevention field.</ce:para>
                  <ce:para id="p0035" view="all">Among all the reported STAT3 inhibitors, only BBI608 (Napabucasin) has been shown to block cancer stem cell pathway activity and is currently in Phase II/III clinical trials for the treatment of a variety of cancers [<ce:cross-ref id="crosref0170" refid="bib37">37</ce:cross-ref>]. To our knowledge, the previous structural modifications of BBI608 mainly focused on the acetyl group at 2-position of furan ring [<ce:cross-refs id="crosrefs0035" refid="bib38 bib39 bib40 bib41 bib42">38–42</ce:cross-refs>] (<ce:cross-ref id="crosref0175" refid="fig2">Fig. 2</ce:cross-ref>
                     <ce:float-anchor refid="fig2"/></ce:float-anchor>), and lack of structural diversity. These finding prompted us to develop new BBI608 derivatives with novel scaffolds and potent antitumor activities using structure-based drug design in this work. Firstly, BBI608 was docked into STAT3 SH2 domain (PDB code: <ce:inter-ref id="intref0010" xlink:href="pdb:1BG1" xlink:type="simple">1BG1</ce:inter-ref>) and the binding mode was shown in <ce:cross-ref id="crosref0180" refid="fig3">Fig. 3</ce:cross-ref>
                     <ce:float-anchor refid="fig3"/></ce:float-anchor>A. The 2-acetylfuran group was located at the pY705 (also named pY+0) site, which is related to the disruption of STAT3 phosphorylation and dimerization of inhibitors, and formed a hydrogen bond with Arg609. However, the other important pocket (pY + X site) stayed vacant and was not occupied by any other group. Accordingly, to improve the binding affinity and find new STAT3 inhibitors, the benzene ring in BBI608 was selected to be cleaved and diverse functional groups were directly introduced into the quinone ring via suitable linkers for reaching the pY + X site (<ce:cross-ref id="crosref0185" refid="fig2">Fig. 2</ce:cross-ref>). The binding modes of designed compounds harboring different linkers (<ce:bold>a1</ce:bold>−<ce:bold>a5</ce:bold>) were predicted using docking studies and shown in <ce:cross-ref id="crosref0190" refid="fig3">Fig. 3</ce:cross-ref>B−3F. Considering that the free amine, ie -NH- (linker <ce:bold>a1</ce:bold>), in the compound <ce:bold>A1</ce:bold> could form hydrogen bond with ILE634, <ce:bold>a1</ce:bold> was determined as a privileged linker. As a consequence, various benzene ring derivatives and fragments were then carefully investigated.</ce:para>
               </ce:section>
               <ce:section id="sec2" role="results" view="all">
                  <ce:label>2</ce:label>
                  <ce:section-title id="sectitle0035">Results and discussion</ce:section-title>
                  <ce:section id="sec2.1" view="all">
                     <ce:label>2.1</ce:label>
                     <ce:section-title id="sectitle0040">Chemistry</ce:section-title>
                     <ce:para id="p0040" view="all">The synthetic route for designed compounds was described in <ce:cross-ref id="crosref0195" refid="sch1">Scheme 1</ce:cross-ref>
                        <ce:float-anchor refid="sch1"/></ce:float-anchor>. Upon treatment of commercially available, starting material <ce:bold>10</ce:bold> with bromine and aluminium trichloride, the electrophilic bromination of phenol occurred smoothly to deliver the dibromide <ce:bold>11</ce:bold> [<ce:cross-ref id="crosref0200" refid="bib43">43</ce:cross-ref>]. The <ce:italic>p</ce:italic>-bromophenol <ce:bold>11</ce:bold> was then easily oxidized to quinone <ce:bold>12</ce:bold> as a key intermediate by treatment of chromium oxide and acetic acid [<ce:cross-ref id="crosref0205" refid="bib43">43</ce:cross-ref>]. Finally, the target compounds were readily prepared through Pd-catalyzed C−N cross-coupling reaction with the use of various aromatic or aliphatic amines [<ce:cross-ref id="crosref0210" refid="bib44">44</ce:cross-ref>,<ce:cross-ref id="crosref0215" refid="bib45">45</ce:cross-ref>]. As a representative example, the exact structure of <ce:bold>A24</ce:bold> was unambiguously established by X-ray crystallography (<ce:cross-ref id="crosref0220" refid="fig4">Fig. 4</ce:cross-ref>
                        <ce:float-anchor refid="fig4"/></ce:float-anchor>) [<ce:cross-ref id="crosref0225" refid="bib46">46</ce:cross-ref>].</ce:para>
                  </ce:section>
                  <ce:section id="sec2.2" view="all">
                     <ce:label>2.2</ce:label>
                     <ce:section-title id="sectitle0045">Biological assay</ce:section-title>
                     <ce:section id="sec2.2.1" view="all">
                        <ce:label>2.2.1</ce:label>
                        <ce:section-title id="sectitle0050">In vitro cell growth inhibitory activity</ce:section-title>
                        <ce:para id="p0045" view="all">We firstly evaluated the inhibitory activities of our designed compounds against three STAT3 over-expressed human cancer cell lines (breast cancer cell lines: MDA-MB-231 and MDA-MB-468; human liver carcinoma cell line: HepG2) via established CCK8 assay. The IC<ce:inf loc="post">50</ce:inf> values were listed in <ce:cross-ref id="crosref0230" refid="tbl1">Table 1</ce:cross-ref>
                           <ce:float-anchor refid="tbl1"/></ce:float-anchor> with BBI608 and Stattic as positive controls. In line with our expectations, all compounds displayed potent antiproliferative activities against tested cancer cells and their IC<ce:inf loc="post">50</ce:inf> values ranged from sub-micromole to micromole. Apparently, compounds <ce:bold>A6</ce:bold> and <ce:bold>A11</ce:bold> exhibited considerable or even better inhibitory activities against two breast cancer cell lines compared to BBI608. The preliminary SAR that the additional functional groups occupied the side pocket was summarized as follows: Compound <ce:bold>A6</ce:bold> possessing a 2-CH<ce:inf loc="post">3</ce:inf> and compound <ce:bold>A11</ce:bold> containing a 4-OCH<ce:inf loc="post">3</ce:inf> showed better efficiency than other compounds with a single substituent group installed on the benzene ring (<ce:bold>A7</ce:bold>-<ce:bold>A10</ce:bold>, <ce:bold>A12</ce:bold>-<ce:bold>A20</ce:bold>). Incorporation of two or more substituents on the benzene ring (<ce:bold>A21</ce:bold>-<ce:bold>A25</ce:bold>) caused a slight decrease in activities. Changing phenyl substituent to different size of cycloalkyl substituents (<ce:bold>A26</ce:bold>-<ce:bold>A29</ce:bold>) led to the poor outcome that their corresponding derivatives except for cyclopropyl compound <ce:bold>A26</ce:bold> (0.94–1.97 μM<ce:bold>)</ce:bold> had relatively low potency. In addition, replacement of cyclohexyl group with tetrahydropyranyl substituent had no obvious effect on activities (compounds <ce:bold>A29</ce:bold> vs <ce:bold>A30</ce:bold>). Taken together, compound <ce:bold>A11</ce:bold> showed comprehensive potency <ce:italic>in vitro</ce:italic> anti-tumor activities and was selected for further biological study.</ce:para>
                     </ce:section>
                     <ce:section id="sec2.2.2" view="all">
                        <ce:label>2.2.2</ce:label>
                        <ce:section-title id="sectitle0055">Fluorescence polarization (FP) assay</ce:section-title>
                        <ce:para id="p0050" view="all">It has been reported that STAT3 SH2 domain can bind to 5-FAM-GpYLPQTV-NH<ce:inf loc="post">2</ce:inf> derived peptide with a high affinity and then disrupted STAT3-STAT3 interaction and DNA-binding activity [<ce:cross-ref id="crosref0235" refid="bib47">47</ce:cross-ref>]. To verify the directly binding of the representative compounds <ce:bold>A6</ce:bold> and <ce:bold>A11</ce:bold> to the STAT3 SH2 domain, FP-based competition binding assay was conducted according to previously reported method (<ce:cross-ref id="crosref0240" refid="fig5">Fig. 5</ce:cross-ref>
                           <ce:float-anchor refid="fig5"/></ce:float-anchor>). Firstly, the 5-FAM-GpYLPQTV-NH<ce:inf loc="post">2</ce:inf>derived peptide was applied as the fluorescent probe and showed the Kd value of 174 nM in our experiment, which was almost equivalent to the reported value (Kd = 150 nM) by Berg and coworker [<ce:cross-ref id="crosref0245" refid="bib47">47</ce:cross-ref>]. Then, compound binding assays were performed in a 100 μL volume at a concentration of 10 nM 5-FAM-GpYLPQTV-NH<ce:inf loc="post">2</ce:inf> probe and 160 nM STAT3 protein. As demonstrated in <ce:cross-ref id="crosref0250" refid="fig5">Fig. 5</ce:cross-ref>, compounds <ce:bold>A6</ce:bold> and <ce:bold>A11</ce:bold> bound to STAT3 protein in a concentration-dependent manner with IC<ce:inf loc="post">50</ce:inf> values of 5.55 μM and 5.18 μM, respectively, which indicating the interaction of compounds <ce:bold>A6</ce:bold> and <ce:bold>A11</ce:bold> with the STAT3 SH2 domain.</ce:para>
                     </ce:section>
                     <ce:section id="sec2.2.3" view="all">
                        <ce:label>2.2.3</ce:label>
                        <ce:section-title id="sectitle0060">Compounds <ce:bold>A11</ce:bold> and <ce:bold>A6</ce:bold> inhibited the phosphorylation of STAT3 and its downstream target proteins</ce:section-title>
                        <ce:para id="p0055" view="all">As STAT3 inhibitors can suppress the STAT3 phosphorylation on Tyr705 residue and thus restrain the expression of its downstream target proteins, then we turned our effort to the effects of compound <ce:bold>A11</ce:bold> and <ce:bold>A6</ce:bold> in MDA-MB-231 cells adopting Western blot analysis. As shown in <ce:cross-ref id="crosref0255" refid="fig6">Fig. 6</ce:cross-ref>
                           <ce:float-anchor refid="fig6"/></ce:float-anchor>, compound <ce:bold>A11</ce:bold> and <ce:bold>A6</ce:bold> decreased the STAT3-Y705 phosphorylation in a dose-dependent manner without affecting the total amount of STAT3 protein after 24 h incubation. These results clearly manifested that the decrease of Tyr705 phosphorylated STAT3 was not owing to the constitutional drop of total STAT3 protein, Also, these two representative compounds could decrease the expression of STAT3 target genes, including C-Myc and Cyclin D1, in a dose-dependent manner. It is noteworthy that compound <ce:bold>A11</ce:bold> and <ce:bold>A6</ce:bold> had little impact on the level of STAT1 and its phosphorylation on Tyr701, which suggested that they had a good selectivity against the tumor suppressor STAT1.</ce:para>
                     </ce:section>
                     <ce:section id="sec2.2.4" view="all">
                        <ce:label>2.2.4</ce:label>
                        <ce:section-title id="sectitle0065">Immunofluorescent assay</ce:section-title>
                        <ce:para id="p0060" view="all">To further explore the effect of compound <ce:bold>A11</ce:bold> on STAT3 phosphorylation in MDA-MB-231 cells, immunofluorescent assay was conducted. As expected, after incubation with MDA-MB-231 cells in 3.0 μM for 24 h, compound <ce:bold>A11</ce:bold> markedly reduced the expression of p-STAT3 (p-Tyr705) both in nucleus and cytoplasm compared to the control group (<ce:cross-ref id="crosref0260" refid="fig7">Fig. 7</ce:cross-ref>
                           <ce:float-anchor refid="fig7"/></ce:float-anchor>). The results provided another evidence that <ce:bold>A11</ce:bold> had an intense inhibition on the phosphorylation of STAT3 in MDA-MB-231 cells.</ce:para>
                     </ce:section>
                     <ce:section id="sec2.2.5" view="all">
                        <ce:label>2.2.5</ce:label>
                        <ce:section-title id="sectitle0070">Compound <ce:bold>A11</ce:bold> induced apoptosis in cancer cells</ce:section-title>
                        <ce:para id="p0065" view="all">As we can see in <ce:cross-ref id="crosref0265" refid="tbl1">Table 1</ce:cross-ref>, compound <ce:bold>A11</ce:bold> displayed potent anti-proliferative potency toward three cell lines, we then inquired the effect of <ce:bold>A11</ce:bold> in the induction of MDA-MB-231 cells apoptosis through Annexin-V-FITC/PI staining assay by flow cytometry. As depicted in <ce:cross-ref id="crosref0270" refid="fig8">Fig. 8</ce:cross-ref>
                           <ce:float-anchor refid="fig8"/></ce:float-anchor>, compound <ce:bold>A11</ce:bold> induced the apoptosis of MDA-MB-231 cell in a dose-dependent manner. The apoptosis rates at 0, 1, 2, 4 μM were 6.4%, 11.72%, 17.38%, and 32.28%, respectively, which was consistent with its antitumor efficacy in MDA-MB-231 cells.</ce:para>
                     </ce:section>
                     <ce:section id="sec2.2.6" view="all">
                        <ce:label>2.2.6</ce:label>
                        <ce:section-title id="sectitle0075">Analysis of cell cycle effect</ce:section-title>
                        <ce:para id="p0070" view="all">The effect of compound <ce:bold>A11</ce:bold> on cell cycle progression of MDA-MB-231 cells was assessed using flow cytometry and the results were shown in <ce:cross-ref id="crosref0275" refid="fig9">Fig. 9</ce:cross-ref>
                           <ce:float-anchor refid="fig9"/></ce:float-anchor>. After treating <ce:bold>A11</ce:bold> with MDA-MB-231 cells at the concentration of 0 μM, 1 μM, 2 μM and 4 μM for 24 h, the proportion of cells in S phase increased from 24.65% to 53.40% accompanying with a decrease of cells in G0/G1 phase and G2/M phase. These results suggested that <ce:bold>A11</ce:bold> could dose-dependently cause a significant S phase arrest in MDA-MB-231 cells.</ce:para>
                     </ce:section>
                     <ce:section id="sec2.2.7" view="all">
                        <ce:label>2.2.7</ce:label>
                        <ce:section-title id="sectitle0080">In vivo study of compound <ce:bold>A11</ce:bold>
                        </ce:section-title>
                        <ce:para id="p0075" view="all">We then estimated the in <ce:italic>vivo</ce:italic> anti-tumor activity of compound <ce:bold>A11</ce:bold> using a mouse xenograft model bearing inoculation of human breast cancer cells MDA-MB-231. After the solid tumors were established, compound <ce:bold>A11</ce:bold> was intraperitoneally (i.p.) administered once daily at two doses (5 and 10 mg/kg) for 21 days. As demonstrated in <ce:cross-ref id="crosref0280" refid="fig10">Fig. 10</ce:cross-ref>
                           <ce:float-anchor refid="fig10"/></ce:float-anchor>A and B, the treatment with compound <ce:bold>A11</ce:bold> brought in an obvious reduction of the tumor volume at the dose of 10 mg/kg compared to control group on the twenty-first day (TGI<ce:inf loc="post">TV</ce:inf> = 54.62%). Besides, the tumor weights of mice were notably abated by 45.19% with a dosage of <ce:bold>A11</ce:bold> at 10 mg/kg (<ce:cross-ref id="crosref0285" refid="fig10">Fig. 10</ce:cross-ref>C). What’s more, there was no apparent body-weight loss for those mice treated with compound <ce:bold>A11</ce:bold> at both dosage (<ce:cross-ref id="crosref0290" refid="fig9">Fig. 9</ce:cross-ref>D). Furthermore, the immunofluorescent assay of the tumor tissue revealed that the level of p-STAT3 (Y705) was obviously inhibited by compound <ce:bold>A11</ce:bold> at a dose of 10 mg/kg (<ce:cross-ref id="crosref0295" refid="fig11">Fig. 11</ce:cross-ref>
                           <ce:float-anchor refid="fig11"/></ce:float-anchor>). To sum up, compound <ce:bold>A11</ce:bold> exhibited good <ce:italic>in vivo</ce:italic> anti-tumor capacity and deserved further pharmaceutical studies.</ce:para>
                     </ce:section>
                     <ce:section id="sec2.2.8" view="all">
                        <ce:label>2.2.8</ce:label>
                        <ce:section-title id="sectitle0085">Molecular modeling simulations</ce:section-title>
                        <ce:para id="p0080" view="all">In an attempt to elucidate the binding mode of compound <ce:bold>A11</ce:bold> with STAT3 SH2 domain, docking study was carried out on the basis of the crystal structure of STAT3 homo dimer (PDB code: <ce:inter-ref id="intref0015" xlink:href="pdb:1BG1" xlink:type="simple">1BG1</ce:inter-ref>). For a comparison, the binding mode of BBI608 was also generated and superimposed on that of <ce:bold>A11</ce:bold> (<ce:cross-ref id="crosref0300" refid="fig12">Fig. 12</ce:cross-ref>
                           <ce:float-anchor refid="fig12"/></ce:float-anchor>A). As represented, the p-methoxyphenyl in compound <ce:bold>A11</ce:bold> was extended to the pY + X site, which was not occupied by BBI608 as expected. Such a transformation subsequently gained a hydrogen bond interaction between the methoxy group of <ce:bold>A11</ce:bold> and the guanidyl of ARG595. Moreover, the NH formed a strong hydrogen bond with ILE634 and the distance was 2.0 Å. The other one hydrogen bond (2.5 Å) was engendered between the oxygen atom of acetyl and the amino group of LYS591 (<ce:cross-ref id="crosref0305" refid="fig12">Fig. 12</ce:cross-ref>B). In general, all these interactions ensured the activities of compound <ce:bold>A11</ce:bold> toward STAT3 protein.</ce:para>
                     </ce:section>
                  </ce:section>
               </ce:section>
               <ce:section id="sec3" role="conclusion" view="all">
                  <ce:label>3</ce:label>
                  <ce:section-title id="sectitle0090">Conclusions</ce:section-title>
                  <ce:para id="p0085" view="all">In summary, structure-based drug design strategy was applied to generate new scaffold STAT3 inhibitors based on BBI608. Among them, compound <ce:bold>A11</ce:bold> was evinced to be remarkable anti-tumor activities against MDA-MB-231, MDA-MB-468 and HepG2 cells <ce:italic>in vitro</ce:italic> with an IC<ce:inf loc="post">50</ce:inf> range of 0.67–1.24 μM. The direct interaction between compound <ce:bold>A11</ce:bold> and STAT3 SH2 domain was validated using fluorescence polarization assay with the IC<ce:inf loc="post">50</ce:inf> value of 5.18 μM. Cellular mechanistic studies showed that <ce:bold>A11</ce:bold> can suppress the expression level of phosphorylated STAT3 (p-STAT3) and then downregulated its downstream gene C-Myc and Cyclin D1 without influence the total STAT3 protein. Furthermore, compound <ce:bold>A11</ce:bold> manifested good selectivity against STAT1 which was a member of STAT family and a tumor suppressor. Moreover, <ce:bold>A11</ce:bold> displayed preferable anti-tumor efficacy <ce:italic>in vivo</ce:italic> toward MDA-MB-231 xenograft mouse model at a low dose of 10 mg/kg. Finally, molecular docking study clarified the binding mode of compound <ce:bold>A11</ce:bold> in STAT3 SH2 domain. Collectively, these studies provided more structural reference for the development of STAT3 inhibitors and suggested that compound <ce:bold>A11</ce:bold> might be a highly potent and minimally toxic anti-tumor lead compound worthy of further investigation.</ce:para>
               </ce:section>
               <ce:section id="sec4" view="all">
                  <ce:label>4</ce:label>
                  <ce:section-title id="sectitle0095">Experimental section</ce:section-title>
                  <ce:section id="sec4.1" view="all">
                     <ce:label>4.1</ce:label>
                     <ce:section-title id="sectitle0100">Chemistry</ce:section-title>
                     <ce:para id="p0090" view="all">All solvents and reagents were purchased from commercial suppliers such as Bide pharmatech, Adamas-beta®, etc., and directly used without further purification unless specified. Flash chromatography was performed on silica gel (200–300 mesh) and visualized under UV light monitor (<ce:italic>λ</ce:italic> = 254 nm and 365 nm). The nuclear magnetic resonance (NMR) spectroscopy were recorded in CDCl<ce:inf loc="post">3</ce:inf> or DMSO‑<ce:italic>d</ce:italic>
                        <ce:inf loc="post">6</ce:inf> with Bruker 600 MHz spectrometer (TMS as internal standard) at ambient temperature. The chemical shifts (<ce:italic>δ</ce:italic>) were expressed in parts per million (ppm) downfield and coupling constants (<ce:italic>J</ce:italic>) values were described as hertz. MS was measured on Shimadzu 8040 quadrupole LC/MS system. High-resolution mass spectra (HRMS) data were given by Agilent 6545 Accurate-Mass Q-TOF LC/MS system. The X-Ray crystal structures of compound <ce:bold>A24</ce:bold> was measured on X-ray Single Crystal Diffractometer (Bruker D8 Venture).</ce:para>
                     <ce:section id="sec4.1.1" view="all">
                        <ce:label>4.1.1</ce:label>
                        <ce:section-title id="sectitle0105">Synthesis of 1-(4,6-dibromo-7-hydroxybenzofuran-2-yl)ethan-1-one (<ce:bold>11</ce:bold>)</ce:section-title>
                        <ce:para id="p0095" view="all">To a solution of 1-(7-hydroxybenzofuran-2-yl)ethan-1-one (<ce:bold>10</ce:bold>, 5.0 g, 28.29 mmol) in CH<ce:inf loc="post">2</ce:inf>Cl<ce:inf loc="post">2</ce:inf> (200 mL) was added AlCl<ce:inf loc="post">3</ce:inf> (15.1 g, 113.24 mmol) and the mixture was keeping stirred for 1 h at 40 °C. Then, Br<ce:inf loc="post">2</ce:inf> (10.0 g, 62.57 mmol) was added dropwise to the reaction mixture over 90 min period at 26 °C. The resulting mixture was stirred for 18 h at 26 °C, and poured into ice water, and followed by treatment of sodium thiosulfate. The resulting precipitate was collected by filtration and washed with water, then recrystallized from ethyl acetate to give the compound <ce:bold>11</ce:bold>. Colorless solid; yield: 93.1%. <ce:sup loc="post">1</ce:sup>H NMR (600 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 11.40 (s, 1H),7.86 (s, 1H), 7.72 (s, 1H), 2.61 (s, 3H). ESI-LCMS [M+H]<ce:sup loc="post">+</ce:sup> calcd for C<ce:inf loc="post">10</ce:inf>H<ce:inf loc="post">7</ce:inf>Br<ce:inf loc="post">2</ce:inf>O<ce:inf loc="post">3</ce:inf> 332.88, found: 332.75.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.1.2" view="all">
                        <ce:label>4.1.2</ce:label>
                        <ce:section-title id="sectitle0110">Synthesis of 2-acetyl-6-bromobenzofuran-4,7-dione (<ce:bold>12</ce:bold>)</ce:section-title>
                        <ce:para id="p0100" view="all">To a solution of compound <ce:bold>11</ce:bold> (8.8 g, 26.28 mmol) in 100 mL of 80% acetic acid in water was added CrO<ce:inf loc="post">3</ce:inf> (5.8 g, 52.56 mmol, a solution in 20 mL of water). The reaction mixture was stirred at room temperature for 3 h. After cooling to room temperature, the reaction solution was concentrated in <ce:italic>vacuo</ce:italic> and the residue was dissolved in chloroform. The chloroform phase was washed with water, dried over sodium sulfate, and concentrated in <ce:italic>vacuo</ce:italic>. The residue was purified by column chromatography (PE/EA = 4:1) to give the compound <ce:bold>12</ce:bold>. Yellow solid; yield: 34.5%. <ce:sup loc="post">1</ce:sup>H NMR (600 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 7.46 (s, 1H),7.34 (s, 1H),2.64 (s, 3H). ESI-LCMS [M+H]<ce:sup loc="post">+</ce:sup> calcd for C<ce:inf loc="post">10</ce:inf>H<ce:inf loc="post">6</ce:inf>BrO<ce:inf loc="post">4</ce:inf> 268.94, found: 268.85.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.1.3" view="all">
                        <ce:label>4.1.3</ce:label>
                        <ce:section-title id="sectitle0115">Synthesis of compounds <ce:bold>A1</ce:bold>, <ce:bold>A6-A30</ce:bold>
                        </ce:section-title>
                        <ce:para id="p0105" view="all">To a Schlenk flask was added the corresponding amine (0.20 mmol), 2-acetyl-6-bromobenzofuran-4,7-dione (<ce:bold>12</ce:bold>, 60.0 mg, 0.22 mmol), Pd(OAc)<ce:inf loc="post">2</ce:inf> (5.5 mg, 0.02 mmol), BINAP (14.3 mg, 0.02 mmol), Cs<ce:inf loc="post">2</ce:inf>CO<ce:inf loc="post">3</ce:inf> (293.2 mg, 0.9 mmol) and anhydrous toluene (6.0 mL) under nitrogen atmosphere, respectively. The reaction mixture was refluxed at 120 °C for 8 h. After cooling to room temperature, the mixture was filtered through a pad of Celite and washed with ethyl acetate. The organic solvent was removed under vacuum and the residue was purified by silica-gel column chromatography to give the compounds <ce:bold>A1</ce:bold>, <ce:bold>A6</ce:bold>-<ce:bold>A30</ce:bold>.</ce:para>
                        <ce:section id="sec4.1.3.1" view="all">
                           <ce:label>4.1.3.1</ce:label>
                           <ce:section-title id="sectitle0120">2-Acetyl-6-(phenylamino)benzofuran-4,7-dione (<ce:bold>A1</ce:bold>)</ce:section-title>
                           <ce:para id="p0110" view="all">Purple solid; yield: 32.3%. <ce:sup loc="post">1</ce:sup>H NMR (600 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 7.46 (d, <ce:italic>J</ce:italic> = 4.2 Hz, 2H), 7.43 (d, <ce:italic>J</ce:italic> = 7.8 Hz, 2H), 7.27 (s, 1H), 7.26 (d, <ce:italic>J</ce:italic> = 3.8 Hz, 2H), 6.17 (s, 1H), 2.64 (s, 3H). <ce:sup loc="post">13</ce:sup>C NMR (150 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 187.30, 180.63, 171.62, 155.97, 149.09, 144.46, 137.02, 131.53, 129.82, 126.22, 122.85, 112.53, 100.66, 26.71. ESI-HRMS [M+H]<ce:sup loc="post">+</ce:sup> calcd for C<ce:inf loc="post">16</ce:inf>H<ce:inf loc="post">12</ce:inf>NO<ce:inf loc="post">4</ce:inf> 282.0761, found: 282.0768.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.3.2" view="all">
                           <ce:label>4.1.3.2</ce:label>
                           <ce:section-title id="sectitle0125">2-Acetyl-6-(o-tolylamino)benzofuran-4,7-dione (<ce:bold>A6</ce:bold>)</ce:section-title>
                           <ce:para id="p0115" view="all">Purple solid; yield: 23.2%, <ce:sup loc="post">1</ce:sup>H NMR (600 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 7.45 (s, 1H), 7.31 (d, <ce:italic>J</ce:italic> = 7.5 Hz, 1H), 7.28 (s, 1H), 7.25-7.22 (m, 3H), 5.70 (s, 1H), 2.63 (s, 3H), 2.28 (s, 3H). <ce:sup loc="post">13</ce:sup>C NMR (150 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 187.54, 180.08, 171.97, 155.10, 150.36, 148.56, 136.65, 135.10, 131.56, 130.66, 127.89, 127.40, 127.30, 114.64, 99.06, 27.12, 17.86. ESI-HRMS [M+Na]<ce:sup loc="post">+</ce:sup> calcd for C<ce:inf loc="post">17</ce:inf>H<ce:inf loc="post">13</ce:inf>NNaO<ce:inf loc="post">4</ce:inf> 318.0737, found: 318.0754.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.3.3" view="all">
                           <ce:label>4.1.3.3</ce:label>
                           <ce:section-title id="sectitle0130">2-Acetyl-6-(m-tolylamino)benzofuran-4,7-dione (<ce:bold>A7</ce:bold>)</ce:section-title>
                           <ce:para id="p0120" view="all">Purple solid; yield: 36.6%, <ce:sup loc="post">1</ce:sup>H NMR (600 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 7.46 (s, 1H), 7.42 (s, 1H), 7.31 (t, <ce:italic>J</ce:italic> = 7.4 Hz, 1H), 7.06 (d, <ce:italic>J</ce:italic> = 10.9 Hz, 3H), 6.17 (s, 1H), 2.63 (s, 3H), 2.39 (s, 3H). <ce:sup loc="post">13</ce:sup>C NMR (150 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 187.31, 180.66, 171.67, 155.97, 149.10, 144.48, 139.97, 136.94, 131.57, 129.62, 127.04, 123.33, 119.85, 112.54, 100.62, 26.70, 21.44.</ce:para>
                           <ce:para id="p0125" view="all">ESI-HRMS [M+Na]<ce:sup loc="post">+</ce:sup> calcd for C<ce:inf loc="post">17</ce:inf>H<ce:inf loc="post">13</ce:inf>NNaO<ce:inf loc="post">4</ce:inf> 318.0737, found: 318.0745.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.3.4" view="all">
                           <ce:label>4.1.3.4</ce:label>
                           <ce:section-title id="sectitle0135">2-Acetyl-6-(p-tolylamino)benzofuran-4,7-dione (<ce:bold>A8</ce:bold>)</ce:section-title>
                           <ce:para id="p0130" view="all">Purple solid; yield: 35.4%, <ce:sup loc="post">1</ce:sup>H NMR (600 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 7.45 (s, 1H), 7.41 (s, 1H), 7.23 (d, <ce:italic>J</ce:italic> = 8.1 Hz, 2H), 7.15 (d, <ce:italic>J</ce:italic> = 8.2 Hz, 2H), 6.10 (s, 1H), 2.63 (s, 3H), 2.37 (s, 3H). <ce:sup loc="post">13</ce:sup>C NMR (150 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 187.31, 180.54, 171.69, 155.94, 149.10, 144.76, 136.31, 134.34, 131.62, 130.36, 122.90, 112.56, 100.29, 26.69, 21.03. ESI-HRMS [M+Na]<ce:sup loc="post">+</ce:sup> calcd for C<ce:inf loc="post">17</ce:inf>H<ce:inf loc="post">13</ce:inf>NNaO<ce:inf loc="post">4</ce:inf> 318.0737, found: 318.0744.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.3.5" view="all">
                           <ce:label>4.1.3.5</ce:label>
                           <ce:section-title id="sectitle0140">2-Acetyl-6-((2-methoxyphenyl)amino)benzofuran-4,7-dione (<ce:bold>A9</ce:bold>)</ce:section-title>
                           <ce:para id="p0135" view="all">Purple solid; yield: 30.8%, <ce:sup loc="post">1</ce:sup>H NMR (600 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 7.87 (s, 1H), 7.46 (s, 1H), 7.40-7.38 (m, 1H), 7.20-7.16 (m, 1H), 7.02 (t, <ce:italic>J</ce:italic> = 7.5 Hz, 1H), 6.98 (d, <ce:italic>J</ce:italic> = 8.2 Hz, 1H), 6.24 (s, 1H), 3.93 (s, 3H), 2.63 (s, 3H). <ce:sup loc="post">13</ce:sup>C NMR (150 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 187.35, 180.68, 171.70, 155.84, 151.27, 149.24, 143.62, 131.45, 126.44, 126.13, 121.34, 120.92, 112.52, 111.23, 100.79, 55.79, 26.71. ESI-HRMS [M+H]<ce:sup loc="post">+</ce:sup> calcd for C<ce:inf loc="post">17</ce:inf>H<ce:inf loc="post">14</ce:inf>NO<ce:inf loc="post">5</ce:inf> 312.0866, found: 312.0859.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.3.6" view="all">
                           <ce:label>4.1.3.6</ce:label>
                           <ce:section-title id="sectitle0145">2-Acetyl-6-((3-methoxyphenyl)amino)benzofuran-4,7-dione (<ce:bold>A10</ce:bold>)</ce:section-title>
                           <ce:para id="p0140" view="all">Purple solid; yield: 32.2%, <ce:sup loc="post">1</ce:sup>H NMR (600 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 7.46 (s, 1H), 7.42 (s, 1H), 7.35-7.32 (m, 1H), 6.85 (d, <ce:italic>J</ce:italic> = 7.4 Hz, 1H), 6.79-6.78 (m, 2H), 6.21 (s, 1H), 3.83 (s, 3H), 2.63 (s, 3H). <ce:sup loc="post">13</ce:sup>C NMR (150 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 187.28, 180.63, 171.61, 160.69, 155.98, 149.09, 144.30, 138.19, 131.51, 130.60, 114.97, 112.52, 111.51, 108.76, 101.09, 55.48, 26.69. ESI-HRMS [M+H]<ce:sup loc="post">+</ce:sup> calcd for C<ce:inf loc="post">17</ce:inf>H<ce:inf loc="post">14</ce:inf>NO<ce:inf loc="post">5</ce:inf> 312.0866, found: 312.0866.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.3.7" view="all">
                           <ce:label>4.1.3.7</ce:label>
                           <ce:section-title id="sectitle0150">2-Acetyl-6-((4-methoxyphenyl)amino)benzofuran-4,7-dione (<ce:bold>A11</ce:bold>)</ce:section-title>
                           <ce:para id="p0145" view="all">Purple solid; yield: 15.1%, <ce:sup loc="post">1</ce:sup>H NMR (600 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 7.45 (s, 1H), 7.35 (s, 1H), 7.19 (d, <ce:italic>J</ce:italic> = 8.9 Hz, 2H), 6.95 (d, <ce:italic>J</ce:italic> = 8.9 Hz, 2H), 5.98 (s, 1H), 3.84 (s, 3H), 2.63 (s, 3H). <ce:sup loc="post">13</ce:sup>C NMR (150 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 187.31, 180.42, 171.68, 158.03, 155.94, 149.11, 145.41, 131.72, 129.59, 124.97, 115.01, 112.58, 99.83, 55.58, 26.69. ESI-HRMS [M+H]<ce:sup loc="post">+</ce:sup> calcd for C<ce:inf loc="post">17</ce:inf>H<ce:inf loc="post">14</ce:inf>NO<ce:inf loc="post">5</ce:inf> 312.0866, found: 312.0867.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.3.8" view="all">
                           <ce:label>4.1.3.8</ce:label>
                           <ce:section-title id="sectitle0155">2-Acetyl-6-((2-fluorophenyl)amino)benzofuran-4,7-dione (<ce:bold>A12</ce:bold>)</ce:section-title>
                           <ce:para id="p0150" view="all">Purple solid; yield: 27.5%, <ce:sup loc="post">1</ce:sup>H NMR (600 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 7.46 (s, 1H), 7.41-7.39 (m, 2H), 7.24-7.21 (m, 3H), 6.05 (s, 1H), 2.64 (s, 3H). <ce:sup loc="post">13</ce:sup>C NMR (150 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 187.31, 180.62, 171.26, 156.03, 154.65, 149.15, 144.18, 131.35, 127.32, 125.29, 124.92, 124.07, 116.74, 112.44, 101.85, 26.71. ESI-HRMS [M+H]<ce:sup loc="post">+</ce:sup> calcd for C<ce:inf loc="post">16</ce:inf>H<ce:inf loc="post">11</ce:inf>FNO<ce:inf loc="post">4</ce:inf> 300.0667, found: 300.0679.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.3.9" view="all">
                           <ce:label>4.1.3.9</ce:label>
                           <ce:section-title id="sectitle0160">2-Acetyl-6-((3-fluorophenyl)amino)benzofuran-4,7-dione (<ce:bold>A13</ce:bold>)</ce:section-title>
                           <ce:para id="p0155" view="all">Purple solid; yield: 15.7%, <ce:sup loc="post">1</ce:sup>H NMR (600 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 7.46 (s, 1H), 7.43 (s, 1H), 7.40 (d, <ce:italic>J</ce:italic> = 6.8 Hz, 1H), 7.05 (d, <ce:italic>J</ce:italic> = 7.7 Hz, 1H), 7.01 (d, <ce:italic>J</ce:italic> = 9.4 Hz, 1H), 6.95 (t, <ce:italic>J</ce:italic> = 7.7 Hz, 1H), 6.21 (s, 1H), 2.64 (s, 3H). <ce:sup loc="post">13</ce:sup>C NMR (150 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 187.27, 180.65, 171.38, 164.11, 162.46, 156.07, 149.06, 143.86, 138.67, 131.13, 118.23, 112.94, 112.50, 109.83, 101.60, 26.72. ESI-HRMS [M − H]<ce:sup loc="post">-</ce:sup> calcd for C<ce:inf loc="post">16</ce:inf>H<ce:inf loc="post">9</ce:inf>FNO<ce:inf loc="post">4</ce:inf> 298.0516, found: 298.0517.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.3.10" view="all">
                           <ce:label>4.1.3.10</ce:label>
                           <ce:section-title id="sectitle0165">2-Acetyl-6-((4-fluorophenyl)amino)benzofuran-4,7-dione (<ce:bold>A14</ce:bold>)</ce:section-title>
                           <ce:para id="p0160" view="all">Purple solid; yield: 15.3%, <ce:sup loc="post">1</ce:sup>H NMR (600 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 7.49 (s, 1H), 7.45 (s, 1H), 7.25-7.23 (m, 2H), 7.15 (t, <ce:italic>J</ce:italic> = 8.4 Hz, 2H), 6.01 (s, 1H), 2.62 (s, 3H). <ce:sup loc="post">13</ce:sup>C NMR (150 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 187.26, 175.92, 168.99, 161.90, 160.26, 155.02, 152.69, 143.62, 132.83, 127.12, 124.78, 115.68, 115.53, 111.55, 102.64, 26.73. ESI-HRMS [M+H]<ce:sup loc="post">+</ce:sup> calcd for C<ce:inf loc="post">16</ce:inf>H<ce:inf loc="post">11</ce:inf>FNO<ce:inf loc="post">4</ce:inf> 300.0667, found: 300.0675.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.3.11" view="all">
                           <ce:label>4.1.3.11</ce:label>
                           <ce:section-title id="sectitle0170">2-Acetyl-6-((2-(trifluoromethyl)phenyl)amino)benzofuran-4,7-dione (<ce:bold>A15</ce:bold>)</ce:section-title>
                           <ce:para id="p0165" view="all">Orange solid; yield: 35.8%, <ce:sup loc="post">1</ce:sup>H NMR (600 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 7.76 (d, <ce:italic>J</ce:italic> = 7.9 Hz, 1H), 7.65 (t, <ce:italic>J</ce:italic> = 7.6 Hz, 1H), 7.51 (d, <ce:italic>J</ce:italic> = 8.0 Hz, 1H), 7.49 (s, 1H), 7.46 (s, 1H), 7.41 (t, <ce:italic>J</ce:italic> = 7.5 Hz, 1H), 5.94 (s, 1H), 2.64 (s, 3H). <ce:sup loc="post">13</ce:sup>C NMR (150 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 187.34, 180.65, 171.02, 156.06, 149.06, 145.13, 135.18, 133.15, 131.32, 127.45, 127.42, 126.72, 126.25, 112.36, 101.67, 26.71. ESI-HRMS [M+H]<ce:sup loc="post">+</ce:sup> calcd for C<ce:inf loc="post">17</ce:inf>H<ce:inf loc="post">11</ce:inf>F<ce:inf loc="post">3</ce:inf>NO<ce:inf loc="post">4</ce:inf> 350.0635,found: 350.0632.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.3.12" view="all">
                           <ce:label>4.1.3.12</ce:label>
                           <ce:section-title id="sectitle0175">2-Acetyl-6-((3-(trifluoromethyl)phenyl)amino)benzofuran-4,7-dione (<ce:bold>A16</ce:bold>)</ce:section-title>
                           <ce:para id="p0170" view="all">Purple solid; yield: 29.9%, <ce:sup loc="post">1</ce:sup>H NMR (600 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 7.60-7.56 (m, 1H), 7.51 (s, 2H), 7.48 (d, <ce:italic>J</ce:italic> = 7.3 Hz, 3H), 6.16 (s, 1H), 2.64 (s, 3H). <ce:sup loc="post">13</ce:sup>C NMR (150 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 187.25, 180.60, 171.25, 156.13, 149.01, 143.93, 137.82, 131.43, 130.54, 125.78, 122.73, 122.70, 119.57, 119.55, 112.48, 101.55, 26.73. ESI-HRMS [M+H]<ce:sup loc="post">+</ce:sup> calcd for C<ce:inf loc="post">17</ce:inf>H<ce:inf loc="post">11</ce:inf>F<ce:inf loc="post">3</ce:inf>NO<ce:inf loc="post">4</ce:inf> 350.0635, found: 350.0630.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.3.13" view="all">
                           <ce:label>4.1.3.13</ce:label>
                           <ce:section-title id="sectitle0180">2-Acetyl-6-((4-(trifluoromethyl)phenyl)amino)benzofuran-4,7-dione (<ce:bold>A17</ce:bold>)</ce:section-title>
                           <ce:para id="p0175" view="all">Red solid; yield: 39.1%, <ce:sup loc="post">1</ce:sup>H NMR (600 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 7.76 (d, <ce:italic>J</ce:italic> = 7.8 Hz, 1H), 7.65 (t, <ce:italic>J</ce:italic> = 7.7 Hz, 1H), 7.51 (d, <ce:italic>J</ce:italic> = 8.0 Hz, 1H), 7.49 (s, 1H), 7.45 (s, 1H), 7.41 (t, <ce:italic>J</ce:italic> = 7.7 Hz, 1H), 5.94 (s, 1H), 2.64 (s, 3H). <ce:sup loc="post">13</ce:sup>C NMR (150 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 187.35, 180.66, 171.03, 156.08, 149.08, 145.14, 135.19, 133.17, 131.34, 127.44, 126.74, 126.27, 112.38, 101.69, 26.73. ESI-HRMS [M+H]<ce:sup loc="post">+</ce:sup> calcd for C<ce:inf loc="post">17</ce:inf>H<ce:inf loc="post">11</ce:inf>F<ce:inf loc="post">3</ce:inf>NO<ce:inf loc="post">4</ce:inf> 350.0635, found: 350.0638.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.3.14" view="all">
                           <ce:label>4.1.3.14</ce:label>
                           <ce:section-title id="sectitle0185">2-Acetyl-6-((2-ethylphenyl)amino)benzofuran-4,7-dione (<ce:bold>A18</ce:bold>)</ce:section-title>
                           <ce:para id="p0180" view="all">Purple solid; yield: 24.4%, <ce:sup loc="post">1</ce:sup>H NMR (600 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 7.50 (s, 1H), 7.37 (s, 1H), 7.35-7.33 (m, 1H), 7.29-7.28 (m, 2H), 7.25-7.23 (m, 1H), 5.75 (s, 1H), 2.63-2.60 (m, 5H), 1.22 (t, <ce:italic>J</ce:italic> = 7.6 Hz, 3H). <ce:sup loc="post">13</ce:sup>C NMR (150 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 187.38, 175.97, 169.02, 154.90, 153.03, 144.12, 139.73, 135.09, 128.80, 127.82, 127.12, 125.92, 124.59, 111.60, 101.26, 26.77, 24.82, 13.87. ESI-HRMS [M − H]<ce:sup loc="post">-</ce:sup> calcd for C<ce:inf loc="post">18</ce:inf>H<ce:inf loc="post">14</ce:inf>NO<ce:inf loc="post">4</ce:inf> 308.0923, found: 308.0933.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.3.15" view="all">
                           <ce:label>4.1.3.15</ce:label>
                           <ce:section-title id="sectitle0190">2-Acetyl-6-((4-(dimethylamino)phenyl)amino)benzofuran-4,7-dione (<ce:bold>A19</ce:bold>)</ce:section-title>
                           <ce:para id="p0185" view="all">Purple solid; yield: 65.5%, <ce:sup loc="post">1</ce:sup>H NMR (600 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 7.56 (s, 1H), 7.48 (s, 1H), 7.14 (d, <ce:italic>J</ce:italic> = 8.8 Hz, 2H), 6.73 (d, <ce:italic>J</ce:italic> = 8.8 Hz, 2H), 6.05 (s, 1H), 3.00 (s, 6H), 2.62 (s, 3H).<ce:sup loc="post">13</ce:sup>C NMR (150 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 187.63, 178.41, 174.93, 155.01, 154.34, 149.08, 146.00, 125.33, 124.44, 124.30, 112.83, 111.49, 98.88, 40.52, 26.72. ESI-HRMS [M+H]<ce:sup loc="post">+</ce:sup> calcd for C<ce:inf loc="post">18</ce:inf>H<ce:inf loc="post">17</ce:inf>N<ce:inf loc="post">2</ce:inf>O<ce:inf loc="post">4</ce:inf> 325.1183, found: 325.1169.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.3.16" view="all">
                           <ce:label>4.1.3.16</ce:label>
                           <ce:section-title id="sectitle0195">2-Acetyl-6-((4-isopropoxyphenyl)amino)benzofuran-4,7-dione (<ce:bold>A20</ce:bold>)</ce:section-title>
                           <ce:para id="p0190" view="all">Purple solid; yield: 21.7%, <ce:sup loc="post">1</ce:sup>H NMR (600 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 7.48 (s, 1H), 7.46 (s, 1H), 7.16 (d, <ce:italic>J</ce:italic> = 8.8 Hz, 2H), 6.93 (d, <ce:italic>J</ce:italic> = 8.8 Hz, 2H), 6.02 (s, 1H), 4.58-4.54 (m, 1H), 2.62 (s, 3H), 1.36 (s, 3H), 1.35 (s, 3H). <ce:sup loc="post">13</ce:sup>C NMR (150 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 187.42, 178.26, 175.16, 156.57, 154.60, 154.49, 146.23, 129.11, 124.98, 124.47, 116.89, 111.40, 99.43, 70.43, 26.69, 21.97. ESI-HRMS [M+H]<ce:sup loc="post">+</ce:sup> calcd for C<ce:inf loc="post">19</ce:inf>H<ce:inf loc="post">18</ce:inf>NO<ce:inf loc="post">5</ce:inf> 340.1179, found: 340.1165.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.3.17" view="all">
                           <ce:label>4.1.3.17</ce:label>
                           <ce:section-title id="sectitle0200">2-Acetyl-6-((4-methoxy-2-methylphenyl)amino)benzofuran-4,7-dione (<ce:bold>A21</ce:bold>)</ce:section-title>
                           <ce:para id="p0195" view="all">Purple solid; yield: 22.2%, <ce:sup loc="post">1</ce:sup>H NMR (600 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 7.42 (s, 1H), 7.18 (s, 1H), 7.06 (d, <ce:italic>J</ce:italic> = 8.4 Hz, 1H), 6.76 (s, 1H), 6.73 (d, <ce:italic>J</ce:italic> = 8.2 Hz, 1H), 5.51 (s, 1H), 3.75 (s, 3H), 2.55 (s, 3H), 2.16 (s, 3H). <ce:sup loc="post">13</ce:sup>C NMR (150 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 187.38, 175.96, 169.02, 159.02, 154.83, 153.22, 144.26, 136.43, 128.45, 128.39, 124.40, 115.55, 111.57, 111.24, 100.05, 55.44, 26.77, 18.66. ESI-HRMS [M+H]<ce:sup loc="post">+</ce:sup> calcd for C<ce:inf loc="post">18</ce:inf>H<ce:inf loc="post">16</ce:inf>NO<ce:inf loc="post">5</ce:inf> 326.1023, found: 326.1021.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.3.18" view="all">
                           <ce:label>4.1.3.18</ce:label>
                           <ce:section-title id="sectitle0205">2-Acetyl-6-((2,6-dimethylphenyl)amino)benzofuran-4,7-dione (<ce:bold>A22</ce:bold>)</ce:section-title>
                           <ce:para id="p0200" view="all">Red solid; yield: 11.5%, <ce:sup loc="post">1</ce:sup>H NMR (600 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 7.49 (s, 1H), 7.25 (s, 1H), 7.13 (d, <ce:italic>J</ce:italic> = 8.6 Hz, 1H), 6.83 (s, 1H), 6.80 (dd, <ce:italic>J</ce:italic> = 8.6, 2.3 Hz, 1H), 5.58 (s, 1H), 3.82 (s, 3H), 2.62 (s, 3H), 2.23 (s, 3H). <ce:sup loc="post">13</ce:sup>C NMR (150 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 187.61, 178.26, 175.09, 158.88, 154.70, 154.48, 147.42, 135.45, 127.50, 126.82, 124.55, 116.63, 112.45, 111.40, 99.55, 55.52, 26.72, 18.02. ESI-HRMS [M+Na]<ce:sup loc="post">+</ce:sup> calcd for C<ce:inf loc="post">18</ce:inf>H<ce:inf loc="post">15</ce:inf>NNaO<ce:inf loc="post">4</ce:inf> 332.0893, found: 332.0892.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.3.19" view="all">
                           <ce:label>4.1.3.19</ce:label>
                           <ce:section-title id="sectitle0210">2-Acetyl-6-((4-methoxy-2,6-dimethylphenyl)amino)benzofuran-4,7-dione (<ce:bold>A23</ce:bold>)</ce:section-title>
                           <ce:para id="p0205" view="all">Purple solid; yield: 25.6%, <ce:sup loc="post">1</ce:sup>H NMR (600 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 7.43 (s, 1H), 6.93 (s, 1H), 6.67 (s, 2H), 5.14 (s, 1H), 3.80 (s, 3H), 2.63 (s, 3H), 2.17 (s, 6H). <ce:sup loc="post">13</ce:sup>C NMR (150 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 187.34, 180.21, 171.61, 159.09, 155.91, 149.28, 146.99, 136.97, 131.90, 126.02, 113.99, 113.97, 112.64, 99.96, 55.39, 26.68, 18.28. ESI-HRMS [M+H]<ce:sup loc="post">+</ce:sup> calcd for C<ce:inf loc="post">19</ce:inf>H<ce:inf loc="post">18</ce:inf>NO<ce:inf loc="post">5</ce:inf> 340.1179, found: 340.1179.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.3.20" view="all">
                           <ce:label>4.1.3.20</ce:label>
                           <ce:section-title id="sectitle0215">2-acetyl-6-((3,4-dimethylphenyl)amino)benzofuran-4,7-dione (<ce:bold>A24</ce:bold>)</ce:section-title>
                           <ce:para id="p0210" view="all">Purple solid; yield: 26.1%, <ce:sup loc="post">1</ce:sup>H NMR (600 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 7.45 (s, 1H), 7.40 (s, 1H), 7.17 (d, <ce:italic>J</ce:italic> = 8.0 Hz, 1H), 7.03 (s, 1H), 6.99 (d, <ce:italic>J</ce:italic> = 8.0 Hz, 1H), 6.12 (s, 1H), 2.63 (s, 3H), 2.28 (s, 3H), 2.27 (s, 3H). <ce:sup loc="post">13</ce:sup>C NMR (150 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 187.32, 180.57, 171.73, 155.93, 149.10, 144.74, 138.35, 135.02, 134.58, 131.65, 130.76, 123.99, 120.27, 112.56, 100.22, 26.69, 19.93, 19.36. ESI-HRMS [M+H]<ce:sup loc="post">+</ce:sup> calcd for C<ce:inf loc="post">18</ce:inf>H<ce:inf loc="post">16</ce:inf>NO<ce:inf loc="post">4</ce:inf> 310.1074, found: 310.1083.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.3.21" view="all">
                           <ce:label>4.1.3.21</ce:label>
                           <ce:section-title id="sectitle0220">2-Acetyl-6-((3-fluoro-5-methylphenyl)amino)benzofuran-4,7-dione (<ce:bold>A25</ce:bold>)</ce:section-title>
                           <ce:para id="p0215" view="all">Purple solid; yield: 22.2%, <ce:sup loc="post">1</ce:sup>H NMR (600 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 7.61 (s, 1H), 7.48 (s, 1H), 6.79 (d, <ce:italic>J</ce:italic> = 9.2 Hz, 1H), 6.69 (s, 1H), 6.62 (d, <ce:italic>J</ce:italic> = 9.1 Hz, 1H), 2.64 (s, 3H), 2.36 (s, 3H).<ce:sup loc="post">13</ce:sup>C NMR (150 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 187.26, 175.92, 169.00, 163.22, 155.06, 152.50, 143.30, 140.48, 137.79, 124.98, 121.10, 113.94, 111.58, 109.14, 104.38, 26.75, 21.46. ESI-HRMS [M+H]<ce:sup loc="post">+</ce:sup> calcd for C<ce:inf loc="post">17</ce:inf>H<ce:inf loc="post">13</ce:inf>FNO<ce:inf loc="post">4</ce:inf> 314.0823, found: 314.0834.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.3.22" view="all">
                           <ce:label>4.1.3.22</ce:label>
                           <ce:section-title id="sectitle0225">2-Acetyl-6-(cyclopropylamino)benzofuran-4,7-dione (<ce:bold>A26</ce:bold>)</ce:section-title>
                           <ce:para id="p0220" view="all">Red solid; yield: 39.1%, <ce:sup loc="post">1</ce:sup>H NMR (600 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 7.42 (s, 1H), 6.08 (s, 1H), 5.88 (s, 1H), 2.61 (s, 3H), 2.52 (m, 1H), 0.93 (d, <ce:italic>J</ce:italic> = 6.7 Hz, 2H), 0.69 (s, 2H). <ce:sup loc="post">13</ce:sup>C NMR (150 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 187.57, 177.91, 174.71, 154.75, 154.34, 149.74, 124.59, 111.35, 99.82, 26.69, 24.55, 7.26. ESI-HRMS [M+H]<ce:sup loc="post">+</ce:sup> calcd for C<ce:inf loc="post">13</ce:inf>H<ce:inf loc="post">12</ce:inf>NO<ce:inf loc="post">4</ce:inf> 246.0761, found: 246.0766.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.3.23" view="all">
                           <ce:label>4.1.3.23</ce:label>
                           <ce:section-title id="sectitle0230">2-Acetyl-6-(cyclobutylamino)benzofuran-4,7-dione (<ce:bold>A27</ce:bold>)</ce:section-title>
                           <ce:para id="p0225" view="all">Red solid; yield: 26.3%, <ce:sup loc="post">1</ce:sup>H NMR (600 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 7.43 (s, 1H), 6.12 (s, 1H), 5.40 (s, 1H), 3.92 (dd, <ce:italic>J</ce:italic> = 14.2, 7.0 Hz, 1H), 2.60 (s, 3H), 2.49 (d, <ce:italic>J</ce:italic> = 7.4 Hz, 2H), 2.05-2.02 (m, 2H), 1.94-1.88 (m, 2H). <ce:sup loc="post">13</ce:sup>C NMR (150 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 187.58, 177.91, 174.45, 154.96, 154.29, 147.25, 124.36, 111.38, 98.31, 47.96, 29.92, 26.69, 15.63. ESI-HRMS [M+H]<ce:sup loc="post">+</ce:sup> calcd for C<ce:inf loc="post">14</ce:inf>H<ce:inf loc="post">14</ce:inf>NO<ce:inf loc="post">4</ce:inf> 260.0917, found: 260.0906.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.3.24" view="all">
                           <ce:label>4.1.3.24</ce:label>
                           <ce:section-title id="sectitle0235">2-Acetyl-6-(cyclopentylamino)benzofuran-4,7-dione (<ce:bold>A28</ce:bold>)</ce:section-title>
                           <ce:para id="p0230" view="all">Purple solid; yield: 6.2%, <ce:sup loc="post">1</ce:sup>H NMR (600 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 7.43 (s, 1H), 5.98 (d, <ce:italic>J</ce:italic> = 4.6 Hz, 1H), 5.53 (s, 1H), 3.80-3.74 (m, 1H), 2.60 (s, 3H), 2.10-2.05 (m, 2H), 1.77-1.64 (m, 6H). <ce:sup loc="post">13</ce:sup>C NMR (150 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 187.59, 177.97, 174.34, 155.09, 154.28, 148.08, 124.28, 111.41, 98.29, 54.43, 32.71, 26.69, 24.10. ESI-HRMS [M+H]<ce:sup loc="post">+</ce:sup> calcd for C<ce:inf loc="post">15</ce:inf>H<ce:inf loc="post">16</ce:inf>NO<ce:inf loc="post">4</ce:inf> 274.1074, found: 274.1076.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.3.25" view="all">
                           <ce:label>4.1.3.25</ce:label>
                           <ce:section-title id="sectitle0240">2-Acetyl-6-(cyclohexylamino)benzofuran-4,7-dione (<ce:bold>A29</ce:bold>)</ce:section-title>
                           <ce:para id="p0235" view="all">Purple solid; yield: 25.7%, <ce:sup loc="post">1</ce:sup>H NMR (600 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 7.43 (s, 1H), 5.96 (d, <ce:italic>J</ce:italic> = 5.2 Hz, 1H), 5.53 (s, 1H), 3.30-3.25 (m, 1H), 2.60 (s, 3H), 2.03 (d, <ce:italic>J</ce:italic> = 11.4 Hz, 2H), 1.82-1.80 (m, 2H), 1.70-1.68 (m, 2H), 1.39-1.31 (m, 4H).<ce:sup loc="post">13</ce:sup>C NMR (150 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 187.62, 178.06, 174.48, 155.11, 154.28, 147.45, 124.32, 111.42, 97.69, 51.94, 31.73, 26.70, 25.34, 24.49. ESI-HRMS [M+H]<ce:sup loc="post">+</ce:sup> calcd for C<ce:inf loc="post">16</ce:inf>H<ce:inf loc="post">18</ce:inf>NO<ce:inf loc="post">4</ce:inf> 287.1230, found: 288.1220.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.3.26" view="all">
                           <ce:label>4.1.3.26</ce:label>
                           <ce:section-title id="sectitle0245">2-Acetyl-6-((tetrahydro-2H-pyran-4-yl)amino)benzofuran-4,7-dione (<ce:bold>A30</ce:bold>)</ce:section-title>
                           <ce:para id="p0240" view="all">Red solid; yield: 35.3%, <ce:sup loc="post">1</ce:sup>H NMR (600 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 7.37 (s, 1H), 5.84 (s, 1H), 5.48 (s, 1H), 3.96 (d, <ce:italic>J</ce:italic> = 10.8 Hz, 2H), 3.44 (t, <ce:italic>J</ce:italic> = 10.6 Hz, 3H), 2.54 (s, 3H), 1.96 (d, <ce:italic>J</ce:italic> = 12.3 Hz, 2H), 1.57 (d, <ce:italic>J</ce:italic> = 10.6 Hz, 2H).<ce:sup loc="post">13</ce:sup>C NMR (150 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 187.54, 177.84, 174.56, 154.70, 154.38, 147.09, 124.48, 111.41, 98.13, 66.23, 49.25, 31.75, 26.69. ESI-HRMS [M+H]<ce:sup loc="post">+</ce:sup> calcd for C<ce:inf loc="post">15</ce:inf>H<ce:inf loc="post">16</ce:inf>NO<ce:inf loc="post">5</ce:inf> 290.1023, found: 290.1028.</ce:para>
                        </ce:section>
                     </ce:section>
                  </ce:section>
                  <ce:section id="sec4.2" view="all">
                     <ce:label>4.2</ce:label>
                     <ce:section-title id="sectitle0250">Biological evaluation</ce:section-title>
                     <ce:section id="sec4.2.1" view="all">
                        <ce:label>4.2.1</ce:label>
                        <ce:section-title id="sectitle0255">Cell lines culture</ce:section-title>
                        <ce:para id="p0245" view="all">All cancer cell lines (MDA-MB-231, MDA-MB-468 and HepG2) were purchased from the Cell Bank of Shanghai Institute of Cell Biology, Chinese Academy of Sciences (Shanghai, China). The MDA-MB-231 and MDA-MB-468 cell lines were cultured in Dulbecco Modified Eagle Medium/Nutrient Mixture F-12(DMEM/F-12, Biological Industries, Beit Haemek, Israel), supplemented with 10% (v/v) fetal bovine serum (FBS, Gibco), 50 mg/mL penicillin and 50 mg/mL streptomycin (Biological Industries, Beit Haemek, Israel). While the HepG2 cell line was maintained in high glucose Dulbecco’s Modified Eagle Medium (Biological Industries, Beit Haemek, Israel) replenished with 10% fetal bovine serum, and penicillin/streptomycin. All the cell lines were incubated at 37 °C in a humidified atmosphere containing 5% CO<ce:inf loc="post">2</ce:inf>.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.2.2" view="all">
                        <ce:label>4.2.2</ce:label>
                        <ce:section-title id="sectitle0260">In vitro cell growth inhibitory activity assays</ce:section-title>
                        <ce:para id="p0250" view="all">All of these cancer cells were seeded in 96-well culture plates at a density of 5000–7000 cells per well (100 μL/well) and incubated at 37 °C in a humidified atmosphere containing 5% CO<ce:inf loc="post">2</ce:inf> for 8 h. In succession, different concentrations of test compounds were added in triplicate to the plates in 100 μL fresh mediums (the total volume was 200 μL, DMSO <0.1%) and incubated at 37 °C for 48 h. After removing the cell culture medium, 10% Cell Counting Kit-8 (CCK-8, APExBIO, Houston, USA) solution (100 μL) was administered in the 96-well plates and re-incubated for 4 h (MDA-MB-468, MDA-MB-231) and 1 h (HepG2). Finally, the absorbance was measured at the wavelength of 450 nm by a microplate spectrophotometer (MK3, Thermo, Germany). Each treatment was performed in triplicate. The half inhibitory concentration IC<ce:inf loc="post">50</ce:inf> values were calculated by Prism 7.0 (GraphPad Software).</ce:para>
                     </ce:section>
                     <ce:section id="sec4.2.3" view="all">
                        <ce:label>4.2.3</ce:label>
                        <ce:section-title id="sectitle0265">Fluorescence polarization assay</ce:section-title>
                        <ce:para id="p0255" view="all">The STAT3 protein (His-tag 127–722 amino acid, DetaiBio, China) was diluted to a concentration of 1600 nM and the fluorescently labelled peptide probe (5-FAM-GpYLPQTV-NH2, ChinaPeptides, China) was deliquated to a concentration of 100 nM. Different concentrations of tested compound (10 μL) and prepared STAT3 protein (10 μL) were added to 70 μL assay buffer (Hepes 10 mM PH = 7.5, EDTA 1 mM, NaCl 50 mM, 0.1% Nonidet P40) in 96-well, black round-bottom plates at 37 °C for 30 min. Then 10 μL of fluorescently labelled peptide probe was added and incubated at 37 °C for another 1 h. The polarization values were measured at an excitation wavelength of 485 nm and an emission wavelength of 530 nm, which was detected by Tecan Spark instrument. The half inhibitory concentration IC<ce:inf loc="post">50</ce:inf> values were by Prism 7.0 (GraphPad Software).</ce:para>
                     </ce:section>
                     <ce:section id="sec4.2.4" view="all">
                        <ce:label>4.2.4</ce:label>
                        <ce:section-title id="sectitle0270">Western blot analysis</ce:section-title>
                        <ce:para id="p0260" view="all">MDA-MB-231 cells were incubated with various concentrations of compound <ce:bold>A11</ce:bold> for 24 h and rinsed twice with PBS and then lysed with RIPA buffer (Beyotime Biotechnology) containing a protease inhibitor (PMSF) mixture at 1:100 dilution on ice for 10 min. The lysates were cleared by centrifugation (4 °C, 12,000 rmp, 10 min), and BCA protein assay kit was applied to measure the protein concentration. Equal amount of proteins from the total cell lysates (40 μg per lane) was separated by sodium dodecyl sulfate (10%) polyacrylamide gel electrophoresis (SDS-PAGE, BioRad Laboratories, Hercules, CA), and then electrically transferred to polyvinylidene difluoride (PVDF) membranes (BioRad Laboratories, Hercules, CA). The membranes were blocked with 5% non-fat powdered milk in TBST buffer for 2 h at room temperature, and blotted with primary antibodies specific for STAT3, p-STAT3(Y705), STAT1, p-STAT1(Y701), C-Myc, Cyclin D1 and GAPDH at 4 °C for overnight. After washing out three times (5 min each) with TBST, the corresponding HRP-conjugated secondary antibodies were incubated for 1 h at room temperature. Enhanced chemiluminescence (ECL) and bioanalytical imaging system (Azure biosystems, Inc, C600) were applied for assay of target proteins.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.2.5" view="all">
                        <ce:label>4.2.5</ce:label>
                        <ce:section-title id="sectitle0275">Cell immunofluorescent assay</ce:section-title>
                        <ce:para id="p0265" view="all">After MDA-MB-231 cells were cultured and incubated in confocal dishes at a density of 1 × 10<ce:sup loc="post">4</ce:sup> cells per dish overnight, compound <ce:bold>A11</ce:bold> was added and incubated for 24 h. Then, cells were fixed with 4% paraformaldehyde and permeabilized with 0.5% Triton X-100 for 15 min respectively. Subsequently, they were sealed with 5% BSA for 1 h and fostered with the specific primary antibody against STAT3 overnight at 4 °C. Next, the Alexa-conjugated secondary antibody (Alexa Fluor 546 goat anti-rabbit IgG, Invitrogen, A-11035) was added and incubated at room temperature for 1 h. Cell nucleus were stained with Hoechst for 10 min. Finally, the cells images were tested and analyzed by a fluorescence microscope (Nikon Eclipse Ti2).</ce:para>
                     </ce:section>
                     <ce:section id="sec4.2.6" view="all">
                        <ce:label>4.2.6</ce:label>
                        <ce:section-title id="sectitle0280">Flow cytometry analysis of apoptotic cells</ce:section-title>
                        <ce:para id="p0270" view="all">MDA-MB-231 cells at a density of 2 × 10<ce:sup loc="post">5</ce:sup> per well were cultured in regular growth medium in 6-well plates for 24 h and disposed in duplicate with various concentrations of compound <ce:bold>A11</ce:bold> for 24 h. Then the cells were trypsinized, was rinsed twice with PBS (centrifugation at 2000 rpm, 5 min) and collected for the next step. After resuspending the cells in 500 μL of binding buffer, 5 μL Annexin V-FITC and 5 μL propidium iodide were added and mixed gently. Finally, the mixture was incubated for 15 min at room temperature in dark and detected by a flow cytometer (Beckman coulter, Inc, A00-1-1102).</ce:para>
                     </ce:section>
                     <ce:section id="sec4.2.7" view="all">
                        <ce:label>4.2.7</ce:label>
                        <ce:section-title id="sectitle0285">Cell cycle effect</ce:section-title>
                        <ce:para id="p0275" view="all">MDA-MB-231 cells were seeded in 6-well plates at density of 2 × 10<ce:sup loc="post">5</ce:sup> cells/well. After overnight adherence, they were incubated with various concentrations of <ce:bold>A11</ce:bold> for 24 h. The treated cells were collected by centrifugation, washed with PBS and fixed in ice-cold 70% ethanol. Then incubated for 30 min at 37 °C with PI containing RNase (MA0334, Dalian Meilun Biotdchnology Co, LTD). The samples were then analyzed by flow cytometry (Beckman coulter, Inc, A00-1-1102).</ce:para>
                     </ce:section>
                     <ce:section id="sec4.2.8" view="all">
                        <ce:label>4.2.8</ce:label>
                        <ce:section-title id="sectitle0290">In vivo studies</ce:section-title>
                        <ce:para id="p0280" view="all">All procedures were performed according to the National Institutes of Health Guidelines for the Care and Use of Laboratory Animals and were approved by the local animal ethics committees. Human breast tumor MDA-MB-231 cells (5 × 10<ce:sup loc="post">6</ce:sup>) were injected into the subcutaneous tissue of five weeks old female BALB/c nude mice (16–18 g). When the tumor volume reached around 50 mm<ce:sup loc="post">3</ce:sup>, the mice were randomly classified into three groups (six mice per group) and intraperitoneally treated with compound <ce:bold>A11</ce:bold> at a dosage of 5 mg/kg or 10 mg/kg daily for 21 days. Simultaneity, the tumor volume was measured once every three days and numerated by the formula: length × width<ce:sup loc="post">2</ce:sup>/2, and the body weight of mice was meted and registered. At terminal phase, all mice were sacrificed and the tumor was segregated, and weighed. The levels of p-STAT3 in tumor tissues were analyzed by the immunofluorescent assay.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.2.9" view="all">
                        <ce:label>4.2.9</ce:label>
                        <ce:section-title id="sectitle0295">Tissue immunofluorescent assay</ce:section-title>
                        <ce:para id="p0285" view="all">The pre-treated and fixed tumor sections were incubated with antibody against p-STAT3 at 4 °C overnight. After scouring with PBST three times, the Alexa-conjugated secondary antibody (Cy3-AffiniPure Goat Anti-Rabbit IgG(H + L), Jackson, 111-165-003) was added and reared at 37 °C for 40 min. Cell nucleus was dyed with DAPI (4’, 6-Diamidino-2-Phenylindole) for 10 min. Finally, the cells images were detected and resolved by a fluorescence microscope (Nikon Eclipse Ti2).</ce:para>
                     </ce:section>
                  </ce:section>
                  <ce:section id="sec4.3" view="all">
                     <ce:label>4.3</ce:label>
                     <ce:section-title id="sectitle0300">Molecular docking</ce:section-title>
                     <ce:para id="p0290" view="all">Molecular docking study was executed applying Schrodinger software package. Firstly, the X-ray crystal structure of STAT3 was retrieved from Protein Data Bank (PDB code: <ce:inter-ref id="intref0020" xlink:href="pdb:1BG1" xlink:type="simple">1BG1</ce:inter-ref>) and prepared with the Protein Preparation Wizard model including the removement of one monomer, the addition of missing hydrogen atoms, the assignment of bond order, assessment of the correct protonation states, and a restrained minimization using the OPLS-2005 force field. Then, the receptor grid was generated at the centroid of selected residues (LYS591, ARG595) and the grid box size was set to 20 Å. After preparing the ligands, molecular docking was carried out using the standard precision (SP) with the default settings. Finally, the pictures were generated using pymol software.</ce:para>
                  </ce:section>
                  <ce:section id="sec4.4" view="all">
                     <ce:label>4.4</ce:label>
                     <ce:section-title id="sectitle0305">X-ray crystal structure determination of compound <ce:bold>A24</ce:bold>
                     </ce:section-title>
                     <ce:para id="p0295" view="all">The D8 venture diffractometer view of compound <ce:bold>A24</ce:bold> is shown in <ce:cross-ref id="crosref0310" refid="fig4">Fig. 4</ce:cross-ref>. The crystal data and structure refinement were emerged in supporting information. The compound was crystallized in the monoclinic space group P2(1)/c with 4 molecules in the unit cell and the structure was solved by direct method with the SHELXTL program package. All the crystallographic parameters (excluding structure factors) of this structure have been deposited in the Cambridge Crystallographic Data Center as supplementary publication number CCDC 1973547. Copies of the data can be obtained, free of charge, on application to CCDC, 12 Union Road, Cambridge CB2 1EZ, UK [fax: +44 (0) 223 336033 or e-mail: <ce:inter-ref id="intref0025" xlink:href="mailto:deposit@ccdc.cam.ac.uk" xlink:type="simple">deposit@ccdc.cam.ac.uk</ce:inter-ref>.</ce:para>
                  </ce:section>
               </ce:section>
            </ce:sections>
            <ce:conflict-of-interest id="coi0010" view="all">
               <ce:section-title id="sectitle0310">Declaration of competing interest</ce:section-title>
               <ce:para id="p0300" view="all">The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</ce:para>
            </ce:conflict-of-interest>
            <ce:acknowledgment id="ack0010" view="all">
               <ce:section-title id="sectitle0315">Acknowledgement</ce:section-title>
               <ce:para id="p0305" view="all">Financial support was generously provided by the <ce:grant-sponsor id="gs1" sponsor-id="https://doi.org/10.13039/501100001809" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor" xlink:type="simple">National Natural Science Foundation of China</ce:grant-sponsor> (Nos. <ce:grant-number refid="gs1">81903423</ce:grant-number> and <ce:grant-number refid="gs1">21871184</ce:grant-number>), the <ce:grant-sponsor id="gs2" sponsor-id="https://doi.org/10.13039/501100002858" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor" xlink:type="simple">China Postdoctoral Science Foundation</ce:grant-sponsor> (<ce:grant-number refid="gs2">2018M642064</ce:grant-number>), the <ce:grant-sponsor id="gs5" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor" xlink:type="simple">Shanghai Sailing Program</ce:grant-sponsor> (<ce:grant-number refid="gs5">19YF1449300</ce:grant-number>), the <ce:grant-sponsor id="gs3" sponsor-id="https://doi.org/10.13039/501100003395" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor" xlink:type="simple">Shanghai Municipal Education Commission</ce:grant-sponsor> (<ce:grant-number refid="gs3">2019-01-07-00-10-E00072</ce:grant-number>), and the <ce:grant-sponsor id="gs4" sponsor-id="https://doi.org/10.13039/501100003399" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor" xlink:type="simple">Science and Technology Commission of Shanghai Municipality</ce:grant-sponsor> (<ce:grant-number refid="gs4">18401933500</ce:grant-number>).</ce:para>
            </ce:acknowledgment>
            <ce:appendices view="all">
               <ce:section id="appsec1" view="extended">
                  <ce:label>Appendix A</ce:label>
                  <ce:section-title id="sectitle0320">Supplementary data</ce:section-title>
                  <ce:para id="p0310" view="all">The following is the Supplementary data to this article:</ce:para>
                  <ce:para id="p0315" view="all">Supplementary data related to this article can be found at.<ce:display>
                        <ce:e-component id="mmc1">
                           <ce:label>Multimedia component 1</ce:label>
                           <ce:alt-text id="alttext0015" role="short">Multimedia component 1</ce:alt-text>
                           <ce:link locator="mmc1" xlink:href="pii:S0223523420303998/mmc1" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/46.1" xlink:type="simple"/></ce:link>
                        </ce:e-component>
                     </ce:display>
                  </ce:para>
               </ce:section>
               <ce:section id="appsec2" view="compact-standard">
                  <ce:label>Appendix A</ce:label>
                  <ce:section-title id="sectitle0325">Supplementary data</ce:section-title>
                  <ce:para id="p0320" view="all">Supplementary data to this article can be found online at <ce:inter-ref id="intref0030" xlink:href="https://doi.org/10.1016/j.ejmech.2020.112428" xlink:type="simple">https://doi.org/10.1016/j.ejmech.2020.112428</ce:inter-ref>.</ce:para>
               </ce:section>
            </ce:appendices>
         </body>
         <tail view="all">
            <ce:bibliography id="cebib0010" view="all">
               <ce:section-title id="sectitle0330">References</ce:section-title>
               <ce:bibliography-sec id="cebibsec0010" view="all">
                  <ce:bib-reference id="bib1">
                     <ce:label>[1]</ce:label>
                     <sb:reference id="sref1">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.E.</ce:given-name>
                                 <ce:surname>Darnell</ce:surname>
                                 <ce:suffix>Jr.</ce:suffix>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Transcription factors as targets for cancer therapy</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Canc.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>2</sb:volume-nr>
                              </sb:series>
                              <sb:date>2002</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>740</sb:first-page>
                              <sb:last-page>749</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0020">J.E.Jr. Darnell, Transcription factors as targets for cancer therapy, Nat. Rev. Cancer 2 (2002) 740-749.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib2">
                     <ce:label>[2]</ce:label>
                     <sb:reference id="sref2">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Miklossy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.S.</ce:given-name>
                                 <ce:surname>Hilliard</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Turkson</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Therapeutic modulators of STAT signaling for human diseases</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Drug Discov.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>12</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>611</sb:first-page>
                              <sb:last-page>629</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0025">G. Miklossy, T.S. Hilliard, J. Turkson, Therapeutic modulators of STAT signaling for human diseases, Nat. Rev. Drug Discov. 12 (2013) 611-629.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib3">
                     <ce:label>[3]</ce:label>
                     <sb:reference id="sref3">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Fletcher</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>Drewry</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.M.</ce:given-name>
                                 <ce:surname>Shahani</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.D.</ce:given-name>
                                 <ce:surname>Page</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Molecular disruption of oncogenic signal transducer and activator of transcription 3 (STAT3) protein</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Biochem. Cell. Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>87</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>825</sb:first-page>
                              <sb:last-page>833</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0030">S. Fletcher, J.A. Drewry, V.M. Shahani, B.D. Page, Molecular disruption of oncogenic signal transducer and activator of transcription 3 (STAT3) protein, Biochem. Cell. Biol. 87 (2009) 825-833.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib4">
                     <ce:label>[4]</ce:label>
                     <sb:reference id="sref4">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>B.E.</ce:given-name>
                                 <ce:surname>Barton</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.G.</ce:given-name>
                                 <ce:surname>Karras</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.F.</ce:given-name>
                                 <ce:surname>Murphy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Barton</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.F.</ce:given-name>
                                 <ce:surname>Huang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Signal transducer and activator of transcription 3 (STAT3) activation in prostate cancer: direct STAT3 inhibition induces apoptosis in prostate cancer lines</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Canc. Therapeut.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>3</sb:volume-nr>
                              </sb:series>
                              <sb:date>2004</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>11</sb:first-page>
                              <sb:last-page>20</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0035">B.E. Barton, J.G. Karras, T.F. Murphy, A. Barton, H.F. Huang, Signal transducer and activator of transcription 3 (STAT3) activation in prostate cancer: direct STAT3 inhibition induces apoptosis in prostate cancer lines, Mol. Cancer Ther. 3 (2004) 11-20.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib5">
                     <ce:label>[5]</ce:label>
                     <sb:reference id="sref5">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Jove</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The STATs of cancer: new molecular targets come of age</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Canc.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>4</sb:volume-nr>
                              </sb:series>
                              <sb:date>2004</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>97</sb:first-page>
                              <sb:last-page>105</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0040">H. Yu, R. Jove, The STATs of cancer: new molecular targets come of age, Nat. Rev. Cancer 4 (2004) 97-105.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib6">
                     <ce:label>[6]</ce:label>
                     <sb:reference id="sref6">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Hermann</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Buenttner</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Jove</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Revisiting STAT3 signalling in cancer: new and unexpected biological functions</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Canc.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>14</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>737</sb:first-page>
                              <sb:last-page>746</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0045">H. Yu, H. Lee, A. Hermann, R. Buenttner, R. Jove, Revisiting STAT3 signalling in cancer: new and unexpected biological functions, Nat. Rev. Cancer. 14 (2014) 737-746.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib7">
                     <ce:label>[7]</ce:label>
                     <sb:reference id="sref7">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Turkson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Ryan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.S.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Haura</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Laundano</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Sebti</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.D.</ce:given-name>
                                 <ce:surname>Hamilton</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Jove</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Biol. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>276</sb:volume-nr>
                              </sb:series>
                              <sb:date>2001</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>45443</sb:first-page>
                              <sb:last-page>45455</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0050">J. Turkson, D. Ryan, J.S. Kim, Y. Zhang, Z. Chen, E. Haura, A. Laundano, S. Sebti, A.D. Hamilton, R. Jove, Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation, J. Biol. Chem. 276 (2001) 45443-45455.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib8">
                     <ce:label>[8]</ce:label>
                     <sb:reference id="sref8">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.M.</ce:given-name>
                                 <ce:surname>McDaniel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.E.</ce:given-name>
                                 <ce:surname>Varley</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Gertz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.S.</ce:given-name>
                                 <ce:surname>Savic</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.S.</ce:given-name>
                                 <ce:surname>Roberts</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.K.</ce:given-name>
                                 <ce:surname>Bailey</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.A.</ce:given-name>
                                 <ce:surname>Shevde</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.C.</ce:given-name>
                                 <ce:surname>Ramaker</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.N.</ce:given-name>
                                 <ce:surname>Lasseigne</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.K.</ce:given-name>
                                 <ce:surname>Kirby</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.M.</ce:given-name>
                                 <ce:surname>Newberry</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.C.</ce:given-name>
                                 <ce:surname>Partridge</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.L.</ce:given-name>
                                 <ce:surname>Jones</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Boone</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.E.</ce:given-name>
                                 <ce:surname>Levy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.G.</ce:given-name>
                                 <ce:surname>Oliver</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.C.</ce:given-name>
                                 <ce:surname>Sexton</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.E.</ce:given-name>
                                 <ce:surname>Grizzle</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Forero</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.J.</ce:given-name>
                                 <ce:surname>Buchsbaum</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.J.</ce:given-name>
                                 <ce:surname>Cooper</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.M.</ce:given-name>
                                 <ce:surname>Myers</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Genomic regulation of invasion by STAT3 in triple negative breast cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncotarget</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>8</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>8226</sb:first-page>
                              <sb:last-page>8238</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0055">J.M. McDaniel, K.E. Varley, J. Gertz, D.S. Savic, B.S. Roberts, S.K. Bailey, L.A. Shevde, R.C. Ramaker, B.N. Lasseigne, M.K. Kirby, K.M. Newberry, E.C. Partridge, A.L. Jones, B. Boone, S.E. Levy, P.G. Oliver, K.C. Sexton, W.E. Grizzle, A. Forero, D.J. Buchsbaum, S.J. Cooper, R.M. Myers, Genomic regulation of invasion by STAT3 in triple negative breast cancer, Oncotarget 8 (2017) 8226-8238.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib9">
                     <ce:label>[9]</ce:label>
                     <sb:reference id="sref9">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.L.</ce:given-name>
                                 <ce:surname>Koskela</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Eldfors</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Ellonen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.J.</ce:given-name>
                                 <ce:surname>van Adrichem</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Kuusanmaki</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.I.</ce:given-name>
                                 <ce:surname>Andersson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Lagstrom</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.J.</ce:given-name>
                                 <ce:surname>Clemente</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Olson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.E.</ce:given-name>
                                 <ce:surname>Jalkanen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.M.</ce:given-name>
                                 <ce:surname>Majumder</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Almusa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Edgren</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Lepisto</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Mattila</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Guinta</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Koistinen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Kuittinen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Penttinen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Parsons</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Knowles</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Saarela</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Wennerberg</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Kallioniemi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Porkka</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.P.</ce:given-name>
                                 <ce:surname>Loughran</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.A.</ce:given-name>
                                 <ce:surname>Heckman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.P.</ce:given-name>
                                 <ce:surname>Maciejewski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Mustjoki</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Somatic STAT3 mutations in large granular lymphocytic leukemia</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>N. Engl. J. Med.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>366</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1905</sb:first-page>
                              <sb:last-page>1913</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0060">H.L. Koskela, S. Eldfors, P. Ellonen, A.J. van Adrichem, H. Kuusanmaki, E.I. Andersson, S. Lagstrom, M.J. Clemente, T. Olson, S.E. Jalkanen, M.M. Majumder, H. Almusa, H. Edgren, M. Lepisto, P. Mattila, K. Guinta, P. Koistinen, T. Kuittinen, K. Penttinen, A. Parsons, J. Knowles, J. Saarela, K. Wennerberg, O. Kallioniemi, K. Porkka, T.P. Loughran, C.A. Heckman, J.P. Maciejewski, S. Mustjoki, Somatic STAT3 mutations in large granular lymphocytic leukemia, N. Engl. J. Med. 366 (2012) 1905-1913</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib10">
                     <ce:label>[10]</ce:label>
                     <sb:reference id="sref10">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Kortylewski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Pardoll</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Immunol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>7</sb:volume-nr>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>41</sb:first-page>
                              <sb:last-page>51</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0065">H. Yu, M. Kortylewski, D. Pardoll, Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment, Nat. Rev. Immunol. 7 (2007) 41-51.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib11">
                     <ce:label>[11]</ce:label>
                     <sb:reference id="sref11">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.V.</ce:given-name>
                                 <ce:surname>Villarino</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Kanno</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.R.</ce:given-name>
                                 <ce:surname>Ferdinand</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.J.</ce:given-name>
                                 <ce:surname>O’Shea</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Mechanisms of Jak/STAT signaling in immunity and disease</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Immunol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>194</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>21</sb:first-page>
                              <sb:last-page>27</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0070">A.V. Villarino, Y. Kanno, J.R. Ferdinand, J.J. O’Shea, Mechanisms of Jak/STAT signaling in immunity and disease, J. Immunol. 194 (2015) 21-27.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib12">
                     <ce:label>[12]</ce:label>
                     <sb:reference id="sref12">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.E.</ce:given-name>
                                 <ce:surname>Johnson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.A.</ce:given-name>
                                 <ce:surname>O’Keefe</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.R.</ce:given-name>
                                 <ce:surname>Grandis</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Targeting the IL-6/JAK/STAT3 signalling axis in cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Clin. Oncol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>15</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>234</sb:first-page>
                              <sb:last-page>248</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0075">D.E. Johnson, R.A. O’Keefe, J.R. Grandis, Targeting the IL-6/JAK/STAT3 signalling axis in cancer, Nat. Rev. Clin. Oncol. 15 (2018) 234-248.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib13">
                     <ce:label>[13]</ce:label>
                     <sb:reference id="sref13">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.E.</ce:given-name>
                                 <ce:surname>Darnell</ce:surname>
                                 <ce:suffix>Jr.</ce:suffix>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Transcription factors as targets for cancer therapy</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Canc.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>2</sb:volume-nr>
                              </sb:series>
                              <sb:date>2002</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>740</sb:first-page>
                              <sb:last-page>749</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0080">J.E. Darnell Jr., Transcription factors as targets for cancer therapy, Nat. Rev. Cancer 2 (2002) 740-749</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib14">
                     <ce:label>[14]</ce:label>
                     <sb:reference id="sref14">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Huang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Zhong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Dong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Zheng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Shi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Zhu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Qu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Hu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Revisiting signal transducer and activator of transcription 3 (STAT3) as an anticancer target and its inhibitor discovery: where are we and where should we go?</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>187</sb:volume-nr>
                              </sb:series>
                              <sb:date>2020</sb:date>
                           </sb:issue>
                           <ce:doi>10.1016/j.ejmech.2019.111922</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0085">Q. Huang, Y. Zhong, H. Dong, Q. Zheng, S. Shi, K. Zhu, X. Qu, W. Hu, X. Zhang, Y. Wang, Revisiting signal transducer and activator of transcription 3 (STAT3) as an anticancer target and its inhibitor discovery: Where are we and where should we go? Eur. J. Med. Chem. 187 (2020) DOI: 10.1016/j.ejmech.2019.111922.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib15">
                     <ce:label>[15]</ce:label>
                     <sb:reference id="sref15">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Song</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A low-molecular weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Proc. Natl. Acad. Sci. U. S. A</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>102</sb:volume-nr>
                              </sb:series>
                              <sb:date>2005</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4700</sb:first-page>
                              <sb:last-page>4705</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0090">H. Song, R. Wang, S. Wang, J. Lin, A low-molecular weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells, Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 4700-4705.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib16">
                     <ce:label>[16]</ce:label>
                     <sb:reference id="sref16">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Hutzen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.K.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Ball</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Zuo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>DeAngelis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Foust</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Sobo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Friedman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Bhasin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Cen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A novel small molecule, LLL12, inhibits STAT3 phosphorylation and activities and exhibits potent growth-suppressive activity in human cancer cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Neoplasia</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>12</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>39</sb:first-page>
                              <sb:last-page>50</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0095">L. Lin, B. Hutzen, P.K. Li, S. Ball, M. Zuo, S. DeAngelis, E. Foust, M. Sobo, L. Friedman, D. Bhasin, L. Cen, C. Li, J. Lin, A novel small molecule, LLL12, inhibits STAT3 phosphorylation and activities and exhibits potent growth-suppressive activity in human cancer cells, Neoplasia 12 (2010) 39-50.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib17">
                     <ce:label>[17]</ce:label>
                     <sb:reference id="sref17">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Xiao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of novel STAT3 small molecule inhibitors via in silico site-directed fragment-based drug design</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>56</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4402</sb:first-page>
                              <sb:last-page>4412</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0100">W. Yu, H. Xiao, J. Lin, C. Li, Discovery of novel STAT3 small molecule inhibitors via in silico site-directed fragment-based drug design, J. Med. Chem. 56 (2013) 4402-4412.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib18">
                     <ce:label>[18]</ce:label>
                     <sb:reference id="sref18">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Schust</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Sperl</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Hollis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.U.</ce:given-name>
                                 <ce:surname>Mayer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Berg</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Stattic: a small-molecule inhibitor of STAT3 activation and dimerization</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Chem. Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>13</sb:volume-nr>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1235</sb:first-page>
                              <sb:last-page>1242</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0105">J. Schust, B. Sperl, A. Hollis, T.U. Mayer, T. Berg, Stattic: a small-molecule inhibitor of STAT3 activation and dimerization, Chem. Biol. 13 (2006) 1235-1242.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib19">
                     <ce:label>[19]</ce:label>
                     <sb:reference id="sref19">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Ren</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Duan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>He</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Zhou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Wu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Pan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Pei</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Ding</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Identification of niclosamide as a new small-molecule inhibitor of the STAT3 signaling pathway</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>ACS Med. Chem. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>1</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>454</sb:first-page>
                              <sb:last-page>459</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0110">X. Ren, L. Duan, Q. He, Z. Zhang, Y. Zhou, D. Wu, J. Pan, D. Pei, K. Ding, Identification of niclosamide as a new small-molecule inhibitor of the STAT3 signaling pathway, ACS Med. Chem. Lett. 1 (2010) 454-459.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib20">
                     <ce:label>[20]</ce:label>
                     <sb:reference id="sref20">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Siddiquee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.C.</ce:given-name>
                                 <ce:surname>Guida</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.A.</ce:given-name>
                                 <ce:surname>Blaskovich</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Greedy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.R.</ce:given-name>
                                 <ce:surname>Lawrence</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.L.</ce:given-name>
                                 <ce:surname>Yip</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Jove</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.M.</ce:given-name>
                                 <ce:surname>McLaughlin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.J.</ce:given-name>
                                 <ce:surname>Lawrence</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.S.</ce:given-name>
                                 <ce:surname>Sebti</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Turkson</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Proc. Natl. Acad. Sci. U. S. A</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>104</sb:volume-nr>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>7391</sb:first-page>
                              <sb:last-page>7396</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0115">K. Siddiquee, S. Zhang, W.C. Guida, M.A. Blaskovich, B. Greedy, H.R. Lawrence, M.L. Yip, R. Jove, M.M. McLaughlin, N.J. Lawrence, M.S. Sebti, J. Turkson, Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity, Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 7391-7396.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib21">
                     <ce:label>[21]</ce:label>
                     <sb:reference id="sref21">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Yue</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Fletcher</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.T.</ce:given-name>
                                 <ce:surname>Gunning</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Turkson</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A novel small-molecule disrupts Stat3 SH2 domain-phosphotyrosine interactions and Stat3-dependent tumor processes</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Biochem. Pharmacol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>79</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1398</sb:first-page>
                              <sb:last-page>1409</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0120">X. Zhang, P. Yue, S. Fletcher, W. Zhao, P.T. Gunning, J. Turkson, A novel small-molecule disrupts Stat3 SH2 domain-phosphotyrosine interactions and Stat3-dependent tumor processes, Biochem. Pharmacol. 79 (2010) 1398-1409.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib22">
                     <ce:label>[22]</ce:label>
                     <sb:reference id="sref22">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Xia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.Y.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Luo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Sun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Kong</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of an orally selective inhibitor of signal transducer and activator of transcription 3 using advanced multiple ligand simultaneous docking</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>60</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2718</sb:first-page>
                              <sb:last-page>2731</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0125">W. Yu, C. Li, W. Zhang, Y. Xia, S. Li, J.Y. Lin, K. Yu, M. Liu, L. Yang, J. Luo, Y. Chen, H. Sun, L. Kong, Discovery of an orally selective inhibitor of signal transducer and activator of transcription 3 using advanced multiple ligand simultaneous docking, J. Med. Chem. 60 (2017) 2718-2731.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib23">
                     <ce:label>[23]</ce:label>
                     <sb:reference id="sref23">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.A.</ce:given-name>
                                 <ce:surname>Rogoff</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Keates</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Gao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Murikipudi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Mikule</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Leggett</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.B.</ce:given-name>
                                 <ce:surname>Pardee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.J.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Suppression of cancer relapse and metastasis by inhibiting cancer stemness</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Proc. Natl. Acad. Sci. U. S. A</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>112</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1839</sb:first-page>
                              <sb:last-page>1844</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0130">Y. Li, H.A. Rogoff, S. Keates, Y. Gao, S. Murikipudi, K. Mikule, D. Leggett, W. Li, A.B. Pardee, C.J. Li, Suppression of cancer relapse and metastasis by inhibiting cancer stemness, Proc. Natl. Acad. Sci. U. S. A. 112 (2015) 1839-1844.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib24">
                     <ce:label>[24]</ce:label>
                     <sb:reference id="sref24">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Guo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Cai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Zhu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Song</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Kong</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of new benzensulfonamide derivatives as tripedal STAT3 inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>151</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>752</sb:first-page>
                              <sb:last-page>764</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0135">J. Guo, W. Yu, G. Cai, W. Zhang, S. Li, J. Zhu, D. Song, L. Kong, Discovery of new benzensulfonamide derivatives as tripedal STAT3 inhibitors, Eur. J. Med. Chem. 151 (2018) 752-764.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib25">
                     <ce:label>[25]</ce:label>
                     <sb:reference id="sref25">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Ma</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Guo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Kong</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Antagonizing STAT3 activation with benzo[b]thiophene 1, 1-dioxide based small molecules</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>125</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>538</sb:first-page>
                              <sb:last-page>550</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0140">W. Zhang, T. Ma, S. Li, Y. Yang, J. Guo, W. Yu, L. Kong, Antagonizing STAT3 activation with benzo[b]thiophene 1, 1-dioxide based small molecules, Eur. J. Med. Chem. 125 (2017) 538-550.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib26">
                     <ce:label>[26]</ce:label>
                     <sb:reference id="sref26">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Cai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Song</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Guo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Zhu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Ren</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Kong</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of fluorescent coumarin-benzo[b]thiophene 1, 1-dioxide conjugates as mitochondria-targeting antitumor STAT3 inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>174</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>236</sb:first-page>
                              <sb:last-page>251</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0145">G. Cai, W. Yu, D. Song, W. Zhang, J. Guo, J. Zhu, Y. Ren, L. Kong, Discovery of fluorescent coumarin-benzo[b]thiophene 1, 1-dioxide conjugates as mitochondria-targeting antitumor STAT3 inhibitors, Eur. J. Med. Chem. 174 (2019) 236-251.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib27">
                     <ce:label>[27]</ce:label>
                     <sb:reference id="sref27">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Cai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Zhu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Guo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Yin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Kong</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A new synthetic derivative of cryptotanshinone KYZ3 as STAT3 inhibitor for triple-negative breast cancer therapy</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cell Death Dis.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>9</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1098</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0150">W. Zhang, W. Yu, G. Cai, J. Zhu, C. Zhang, S. Li, J. Guo, G. Yin, C. Chen, L. Kong, A new synthetic derivative of cryptotanshinone KYZ3 as STAT3 inhibitor for triple-negative breast cancer therapy, Cell Death Dis. 9 (2018) 1098.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib28">
                     <ce:label>[28]</ce:label>
                     <sb:reference id="sref28">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Zhu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of novel inhibitors of signal transducer and activator of transcription 3 (STAT3) signaling pathway by virtual screening</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>62</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>301</sb:first-page>
                              <sb:last-page>310</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0155">M. Zhang, W. Zhu, Y. Li, Discovery of novel inhibitors of signal transducer and activator of transcription 3 (STAT3) signaling pathway by virtual screening, Eur. J. Med. Chem. 62 (2013) 301-310.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib29">
                     <ce:label>[29]</ce:label>
                     <sb:reference id="sref29">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Gao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Xiao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Design, synthesis and biological evaluation of benzyloxyphenyl-methylaminophenol derivatives as STAT3 signaling pathway inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>24</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2549</sb:first-page>
                              <sb:last-page>2558</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0160">D. Gao, Q. Xiao, M. Zhang, Y. Li, Design, synthesis and biological evaluation of benzyloxyphenyl-methylaminophenol derivatives as STAT3 signaling pathway inhibitors, Bioorg. Med. Chem. 24 (2016) 2549-2558.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib30">
                     <ce:label>[30]</ce:label>
                     <sb:reference id="sref30">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Lai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Chuang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Chang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Tsai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Huang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Wu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Teng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Pan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Mehndiratta</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Liou</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>N-Sulfonyl-aminobiaryls as antitubulin agents and inhibitors of signal transducers and activators of transcription 3 (STAT3) signaling</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>58</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>6549</sb:first-page>
                              <sb:last-page>6558</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0165">M. Lai, H. Lee, H. Chuang, L. Chang, A. Tsai, M. Chen, H. Huang, Y. Wu, C. Teng, S. Pan, Y. Liu, S. Mehndiratta, J. Liou, N-Sulfonyl-aminobiaryls as Antitubulin Agents and Inhibitors of Signal Transducers and Activators of Transcription 3 (STAT3) Signaling, J. Med. Chem. 58 (2015) 6549-6558.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib31">
                     <ce:label>[31]</ce:label>
                     <sb:reference id="sref31">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>He</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Wu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Guo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Du</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Fang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Zheng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Ye</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Design, synthesis and activity of novel 2,6-disubstituted purine derivatives, potential small molecule inhibitors of signal transducer and activator of transcription 3</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>179</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>218</sb:first-page>
                              <sb:last-page>232</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0170">X. Wang, Q. He, K. Wu, T. Guo, X. Du, H. Zhang, L. Fang, N. Zheng, Q. Zhang, F. Ye, Design, synthesis and activity of novel 2,6-disubstituted purine derivatives, potential small molecule inhibitors of signal transducer and activator of transcription 3, Eur. J. Med. Chem. 179 (2019) 218-232.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib32">
                     <ce:label>[32]</ce:label>
                     <sb:reference id="sref32">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Bai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Zhou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Chinnaswamy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>McEachern</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.Y.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Jiang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Wen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Kumar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.L.</ce:given-name>
                                 <ce:surname>Meagher</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Sun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>Stuckey</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A potent and selective small-molecule degrader of STAT3 achieves complete tumor regression in vivo</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Canc. Cell</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>36</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>498</sb:first-page>
                              <sb:last-page>511</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0175">L. Bai, H. Zhou, R. Xu, Y. Zhao, K. Chinnaswamy, D. McEachern, J. Chen, C.Y. Yang, Z. Liu, M. Wang, L. Liu, H. Jiang, B. Wen, P. Kumar, J.L. Meagher, D. Sun, J.A. Stuckey, S. Wang, A potent and selective small-molecule degrader of STAT3 achieves complete tumor regression in vivo, Cancer Cell 36 (2019) 498-511.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib33">
                     <ce:label>[33]</ce:label>
                     <sb:reference id="sref33">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Zhou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Bai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>McEachern</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Chinnaswamy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Wen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Dai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Kumar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.L.</ce:given-name>
                                 <ce:surname>Meagher</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Yi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Sun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>Stuckey</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Structure-based discovery of SD-36 as a potent, selective, and efficacious PROTAC degrader of STAT3 protein</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>62</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>11280</sb:first-page>
                              <sb:last-page>11300</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0180">H. Zhou, L. Bai, R. Xu, Y. Zhao, J. Chen, D. McEachern, K. Chinnaswamy, B. Wen, L. Dai, P. Kumar, C. Yang, Z. Liu, M. Wang, L. Liu, J.L. Meagher, H. Yi, D. Sun, J.A. Stuckey, S. Wang, Structure-based discovery of SD-36 as a potent, selective, and efficacious PROTAC degrader of STAT3 protein, J. Med. Chem. 62 (2019) 11280-11300.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib34">
                     <ce:label>[34]</ce:label>
                     <sb:reference id="sref34">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.D.</ce:given-name>
                                 <ce:surname>Beebe</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.Y.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.T.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Two decades of research in discovery of anticancer drugs targeting STAT3, how close are we?</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Pharmacol. Ther.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>191</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>74</sb:first-page>
                              <sb:last-page>91</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0185">J.D. Beebe, J.Y. Liu, J.T. Zhang, Two decades of research in discovery of anticancer drugs targeting STAT3, how close are we? Pharmacol Ther. 191 (2018) 74-91.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib35">
                     <ce:label>[35]</ce:label>
                     <sb:reference id="sref35">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.L.</ce:given-name>
                                 <ce:surname>Furtek</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.S.</ce:given-name>
                                 <ce:surname>Backos</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.J.</ce:given-name>
                                 <ce:surname>Matheson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Reigan</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Strategies and approaches of targeting STAT3 for cancer treatment</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>ACS Chem. Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>11</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>308</sb:first-page>
                              <sb:last-page>318</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0190">S.L. Furtek, D.S. Backos, C.J. Matheson, P. Reigan, Strategies and approaches of targeting STAT3 for cancer treatment, ACS Chem. Biol. 11 (2016) 308-318.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib36">
                     <ce:label>[36]</ce:label>
                     <sb:reference id="sref36">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Debnath</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Neamati</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Small molecule inhibitors of signal transducer and activator of transcription 3 (Stat3) protein</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>55</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>6645</sb:first-page>
                              <sb:last-page>6668</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0195">B. Debnath, S. Xu, N. Neamati, Small molecule inhibitors of signal transducer and activator of transcription 3 (Stat3) protein, J. Med. Chem. 55 (2012) 6645-6668.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib37">
                     <ce:label>[37]</ce:label>
                     <sb:reference id="sref37">
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref id="intref0035" xlink:href="https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/napabucasin" xlink:type="simple">https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/napabucasin</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0200">https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/napabucasin</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib38">
                     <ce:label>[38]</ce:label>
                     <sb:reference id="sref38">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>An</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Sang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Ju</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Tong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Luo</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A novel series of napabucasin derivatives as orally active inhibitors of signal transducer and activator of transcription 3 (STAT3)</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>162</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>543</sb:first-page>
                              <sb:last-page>554</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0205">C. Li, C. Chen, Q. An, T. Yang, Z. Sang, Y. Yang, Y. Ju, A. Tong, Y. Luo, A novel series of napabucasin derivatives as orally active inhibitors of signal transducer and activator of transcription 3 (STAT3), Eur. J. Med. Chem. 162 (2019) 543-554.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib39">
                     <ce:label>[39]</ce:label>
                     <sb:reference id="sref39">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Zhou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Peng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Du</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Zhou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Shi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Du</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Sun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Design, synthesis and activity of BBI608 derivatives targeting on stem cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>151</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>39</sb:first-page>
                              <sb:last-page>50</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0210">Q. Zhou, C. Peng, F. Du, L. Zhou, Y. Shi, Y. Du, D. Liu, W. Sun, M. Zhang, G. Chen, Design, synthesis and activity of BBI608 derivatives targeting on stem cells, Eur. J. Med. Chem. 151 (2018) 39-50.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib40">
                     <ce:label>[40]</ce:label>
                     <sb:reference id="sref40">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Reichstein</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Vortherms</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Bannwitz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Tentrop</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Prinz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Muller</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Synthesis and structure-activity relationships of lapacho analogues. 1. Suppression of human keratinocyte hyperproliferation by 2-substituted naphtho[2,3-b]furan-4,9-diones, activation by enzymatic one- and two-electron reduction, and intracellular generation of superoxide</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>55</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>7273</sb:first-page>
                              <sb:last-page>7284</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0215">A. Reichstein, S. Vortherms, S. Bannwitz, J. Tentrop, H. Prinz, K. Muller, Synthesis and structure-activity relationships of lapacho analogues. 1. Suppression of human keratinocyte hyperproliferation by 2-substituted naphtho[2,3-b]furan-4,9-diones, activation by enzymatic one- and two-electron reduction, and intracellular generation of superoxide, J. Med. Chem. 55 (2012) 7273-7284.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib41">
                     <ce:label>[41]</ce:label>
                     <sb:reference id="sref41">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Bannwitz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Krane</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Vortherms</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Kalin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Lindenschmidt</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Zahedi Golpayegani</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Tentrop</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Prinz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Muller</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Synthesis and structure-activity relationships of lapacho analogues. 2. Modification of the basic naphtho[2,3-b]furan-4,9-dione, redox activation, and suppression of human keratinocyte hyperproliferation by 8-hydroxynaphtho[2,3-b]thiophene-4,9-diones</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>57</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>6226</sb:first-page>
                              <sb:last-page>6239</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0220">S. Bannwitz, D. Krane, S. Vortherms, T. Kalin, C. Lindenschmidt, N. Zahedi Golpayegani, J. Tentrop, H. Prinz, K. Muller, Synthesis and structure-activity relationships of lapacho analogues. 2. Modification of the basic naphtho[2,3-b]furan-4,9-dione, redox activation, and suppression of human keratinocyte hyperproliferation by 8-hydroxynaphtho[2,3-b]thiophene-4,9-diones, J. Med. Chem. 57 (2014) 6226-6239.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib42">
                     <ce:label>[42]</ce:label>
                     <sb:reference id="sref42">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Sone</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Hirose</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Shimada</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.J.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Leggett</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>3-substituted Carbonyl-Naphtho[2,3-B]furane Derivative or Pharmaceutically Acceptable Salt Thereof</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:book>
                              <sb:date>2015</sb:date>
                           </sb:book>
                        </sb:host>
                        <sb:comment>WO 2015/12030</sb:comment>
                     </sb:reference>
                     <ce:source-text id="srct0225">T. Sone, W. Hirose, N. Shimada, C.J. Li, W. Li, D. Leggett, 3-substituted Carbonyl-naphtho[2,3-b]furane Derivative or Pharmaceutically Acceptable Salt Thereof, 2015. WO 2015/12030.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib43">
                     <ce:label>[43]</ce:label>
                     <sb:reference id="sref43">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Cai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.B.</ce:given-name>
                                 <ce:surname>Zhong</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Process for preparation of furo[2,3-g]quinoline-4,9-dione compound and medical application, Faming Zhuanli Shenqing</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:book>
                              <sb:title>
                                 <sb:maintitle>CN107501279A20171222. Language: Chinese, Database: Caplus</sb:maintitle>
                              </sb:title>
                              <sb:date>2017</sb:date>
                           </sb:book>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0230">X. Cai, X. B. Zhong, Process for preparation of furo[2,3-g]quinoline-4,9-dione compound and medical application, Faming Zhuanli Shenqing (2017), CN107501279A20171222. Language: Chinese, Database: Caplus.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib44">
                     <ce:label>[44]</ce:label>
                     <sb:reference id="sref44">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Bolibrukh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Khoumeri</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.V.</ce:given-name>
                                 <ce:surname>Polovkovych</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Novikov</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Terme</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Vanelle</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Novel synthesis of 5-Substituted 5H-benzo[b]carbazole-6,11-diones via double Buchwald–Hartwig reaction</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Synlett</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>25</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2765</sb:first-page>
                              <sb:last-page>2768</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0235">K. Bolibrukh, O. Khoumeri, S. V. Polovkovych, V. Novikov, T. Terme, P. Vanelle, Novel synthesis of 5-Substituted 5H-benzo[b]carbazole-6,11-diones via double Buchwald-Hartwig reaction, Synlett 25 (2014) 2765-2768.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib45">
                     <ce:label>[45]</ce:label>
                     <sb:reference id="sref45">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Borah</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Sharma</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Hazarika</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Sharma</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Gogoi</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Synthesis of 1-azaanthraquinone: sequential C–N bond formation/lewis acid catalyzed intramolecular cyclization strategy</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Org. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>82</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>8309</sb:first-page>
                              <sb:last-page>8316</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0240">A. Borah, A. Sharma, H. Hazarika, K. Sharma, P. Gogoi, Synthesis of 1-azaanthraquinone: sequential C-N bond formation/lewis acid catalyzed intramolecular cyclization strategy, J. Org. Chem. 82 (2017) 8309-8316.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib46">
                     <ce:label>[46]</ce:label>
                     <sb:reference id="sref46">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:surname>CCDC 1973547 (A24) contains the supplementary crystallographic data for this paper</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>These data can be obtained free of charge from the Cambridge Crystallographic Data Centre via</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref id="intref0040" xlink:href="http://www.ccdc.cam.ac.uk/data_request/cif" xlink:type="simple">www.ccdc.cam.ac.uk/data_request/cif</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0245">CCDC 1973547 (A24) contains the supplementary crystallographic data for this paper. These data can be obtained free of charge from The Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib47">
                     <ce:label>[47]</ce:label>
                     <sb:reference id="sref47">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Schust</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Berg</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A high-throughput fluorescence polarization assay for signal transducer and activator of transcription 3</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Anal. Biochem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>330</sb:volume-nr>
                              </sb:series>
                              <sb:date>2004</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>114</sb:first-page>
                              <sb:last-page>118</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0250">J. Schust, T. Berg, A high-throughput fluorescence polarization assay for signal transducer and activator of transcription 3, Anal Biochem. 330 (2004) 114-118.</ce:source-text>
                  </ce:bib-reference>
               </ce:bibliography-sec>
            </ce:bibliography>
         </tail>
      </article>
   </xocs:serial-item></xocs:doc></originaltext></full-text-retrieval-response>